A systematic review and meta-analysis of the impact of collaborative practice between community pharmacist and general practitioner on asthma management

This article was published in the following Dove Press journal:
Journal of Asthma and Allergy

Naeem Mubarak^{1,2}
Ernieda Hatah³

Tahir Mehmood Khan⁴
Che Suraya Zin¹

¹Kulliyyah of Pharmacy, Department of Pharmacy Practice, International Islamic University, Kuantan, Malaysia; ²Lahore Pharmacy College, Lahore Medical & Dental College, University of Health Sciences, Lahore, Pakistan; ³Faculty of Pharmacy, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia; ⁴Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan

Objective: This systematic review aims to investigate the impact of collaborative practice between community pharmacist (CP) and general practitioner (GP) in asthma management.

Methods: A systematic search was performed across 10 databases (PubMed, Medline/Ovid, CINAHL, Scopus, Web of Science, Cochrane central register of controlled trials, PsycARTICLES®, Science Direct, Education Resource Information Centre, PRO-Quest), and grey literature using selected MeSH and key words, such as “community pharmacist”, “general practitioner”, and “medicine use review”. The risk of bias of the included studies was assessed by Cochrane risk of bias tool. All studies reporting any of the clinical, humanistic, and economical outcomes using collaborative practice between CPs and GPs in management of asthma, such as CPs conducting medications reviews, patient referrals or providing education and counseling, were included.

Results: A total of 23 studies (six RCTs, four C-RCT, three controlled interventions, seven pre-post, and three case control) were included. In total, 11/14 outcomes were concluded in favor of CP-GP collaborative interventions with different magnitude of effect size. Outcomes, such as asthma severity, asthma control, asthma symptoms, PEF, SABA usage, hospital visit, adherence, and quality of life (QoL) (Asthma Quality-of-Life Questionnaire [AQLQ]; Living with Asthma Questionnaire [LWAQ]) demonstrated a small effect size ($d \geq 0.2$), while inhalation technique, ED visit, and asthma knowledge witnessed medium effect sizes (ES) ($d \geq 0.5$). In addition to that, inhalation technique yielded large ES ($d \geq 0.8$) in RCTs subgroup analysis. However, three outcomes, FEV₁, corticosteroids usage, and preventer-to-reliever ratio, did not hold significant ES ($d < 0.2$) and, thus, remain inconclusive. The collaboration was shown to be value for money in the economic studies in narrative synthesis, however, the limited number of studies hinder pooling of data in meta-analysis.

Conclusion: The findings from this review established a comprehensive evidence base in support of the positive impact of collaborative practice between CP and GP in the management of asthma.

Keywords: community pharmacist, general practitioner, inter-professional collaboration, asthma, collaborative care, clinical outcomes

Correspondence: Che Suraya Zin
Kulliyyah of Pharmacy, Department of Pharmacy Practice, International Islamic University, Universiti Islam Antarabangsa Malaysia Kampus Kuantan, Pahang Darul Makmur, Jalan Sultan Ahmad Shah, Bandar Indera Mahkota, Kuantan, Pahang 25200, Malaysia
Tel +60 111 488 1605
Email chesuraya@iiu.edu.my

Naeem Mubarak
Lahore Pharmacy College, Lahore Medical & Dental College, University of Health Sciences, Lahore, North Tulpura, Canal Bank Road, Lahore 54000, Pakistan
Tel +92 333 555 3729
Email naeem.mubarak@lmdc.edu.pk

Introduction

Among the four major groups of chronic diseases, chronic respiratory diseases have the second highest estimated economic burden for 2011–2025 (US\$ 1.59 trillion) and are responsible for 15% of deaths in the world.¹ Chronic respiratory diseases affect air passages and associated structures of lungs, which lead to either airways'

obstruction or restriction. Examples of chronic respiratory diseases, which are in the headlines for global mortality and morbidity, include asthma, chronic obstructive pulmonary disease, pulmonary hypertension, and occupational lung disease.

Asthma is defined as a “heterogenous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation”.² In low- and middle-income countries, asthma is comparatively more pervasive than any other chronic respiratory disease, and is a prime mover of mortality and disability in all age and gender groups, especially children. In 2015 alone, the death toll due to asthma was 383,000 globally.^{1,3,4}

It is recommended that every country should make updated strategies for efficient diagnosis and medicine management of asthma with an emphasis on capacity building of health professionals. The capacity building may include reinforcing the role of potential healthcare professionals and strengthening the integration of community and primary healthcare by finding innovative ways and new horizons for collaborative efforts and actions.^{1,2,5,6} Effective management of asthma heavily depends on the strategy of medication management to improve adherence and to avoid any medication misadventure. This management of medication is essential, since the patient is taking medications long-term on a daily basis and there are many groups of medications involved in asthma management, such as short acting beta agonist (SABA), long acting beta agonist (LABA), and inhaled steroids.

Involvement of general practitioner in management of asthma

General practitioners (GPs) have generally been involved in asthma management in primary care. However, some studies reported significant shortfalls of GPs' practices to adhere to the standard guidelines and in commissioning written action plans for asthmatic patients, resulting in suboptimal clinical and humanistic outcomes.^{7,8} GPs, however, defend their positions by recounting many barriers in optimization of chronic disease management for asthmatics, for instance, high patient influx, fast growing aging populations, time constraints, and tough schedules, which makes it practically impossible to cater individual detailing and individualized care plans. On the other hand,

patients lack motivation or proper understanding, and do not follow routine scheduled visits due to, for example, financial constraints, and only rush to GPs in the case of medical emergency, such as an acute asthma exacerbation. Together, these factors may contribute to stall effective management of asthma and, hence, call for sharing of responsibilities with other healthcare professionals by involving them in decision-making through a collaborative approach.^{9,10}

Involvement of community pharmacist in management of asthma

The philosophy of pharmaceutical care urges the pharmacist to take responsibility of direct patient care and to improve clinical, humanistic, and economic outcomes, especially in chronic diseases. Community pharmacists (CPs) represent a conspicuous part of pharmacist fraternity, who are equally trained, thoroughly skilled, and well qualified. Recently in developed countries, CPs have been involved in direct patient care for health promotion and medication management services in various chronic diseases, such as hypertension, diabetes, and asthma.¹¹ The expanded role of CPs in patient's education, adherence support, and medication therapy management becomes more important as asthma involves a chronic cycle, specialized devices, periodic assessments, self-monitoring, and an individualized therapeutic plan, and CPs have vast potential to provide these interventions.^{12,13}

Collaboration between CP and GP

Diseases management approaches are receiving volumes of interest in developed countries as a valuable tool to combat with the burden of chronic diseases. A disease management approach is generally comprised of multiple components, such as medication management, education, counseling, monitoring, and use of appropriate guidelines. These approaches, no matters diverse in scope of practice, are based on a common underneath philosophy of “collaboration” among various healthcare stakeholders, such as pharmacists, physicians, and nurses, to deliver a well-coordinated form of collaborative care. Medicines are the major key players in the management of chronic diseases. To improve quality and adherence in the medicine use process and to minimize the risk of any misadventure which chronic use of medicine may cause, medicine management programs were embedded as essential components in diseases management approaches.¹⁴

Collaborative practice such as “Physician-Pharmacist Collaborative Management” or “Collaborative Drug Therapy Management” which involves CPs may offer a peer review of the medication use process and ensure prescribed medications are in accordance to patient disease state. This concept, which was previously confined to tertiary healthcare, are now being practiced in primary healthcare settings such as community pharmacy.¹⁵ However, collaborative practices which involve CP and GP in primary care were less reported. CPs, as being situated at a foremost point of contact with patients, represent a consequential role for relationship building between patients and care-givers. A recent study in the US reveals approximately 250 million people enter pharmacies in a week, making it a unique premises in the sense of high ease of public access.¹⁶ Collaboration in the healthcare system involves mutual communication and sharing of expertise, knowledge, and experience of healthcare professionals, with a prime objective to benefit the patients.¹⁷ Hence, any model which involves two or more healthcare professionals (in this review GP and CP) to improve patient outcomes can be considered as “collaborative practice”. The practice may include, but not be limited to:

- (a) training each other for a proposed intervention,
- (b) referral of patients to each other for diseases or medication counseling or education,
- (c) updating each other about patient drug usage patterns with or without any recommendation, and
- (d) exchange of recommendations, such as change in the medication dose, dosage form, or medicine/drug use review outcomes, or consultation about the course or state of the disease, done by using any form of communication, such as verbal, electronic, or written.

Problem statement

Suboptimal management and burden of asthma

Management of asthma remains suboptimal and represents a global health problem which has raised many concerns to countries’ healthcare systems.^{1,2,5,6} Today, if we appraise the burden of asthma there is much to be worried about. Asthma stands out of the crowd as one of the most high-priced chronic diseases in the world. Economic studies have suggested that a poorly controlled asthma poses a far higher economic burden than a well-controlled asthma.¹⁸ The Global Asthma Report-2018 revealed the

rampant asthma burden, which has amplified from 235 million cases in 2011 to 339 million cases in 2018 around the globe. Physical and psychosocial factors associated with asthma may reduce an individual’s quality-of-life (QoL), causing disabilities, loss of productivity (particularly for pediatrics), deaths, and economic drain. The avoidable deaths related to asthma are still on a surge, with the utmost reason proclaimed to be the mismanagement of diseases and medications including “over-reliance on reliever medication rather than preventer medication”.¹

Lack of adherence and patient education

Lack of adherence to medications, poor knowledge of inhaler technique, triggers, and disease are major contributors in the inadequate management of asthma.¹⁹ Basically, it is pertinent to mention that much of the burden is avoidable, and strategies are required to improve the management of asthma. A recent study in Europe concluded that only 5.3% of the asthma population met the defined clinical goals, and 75% of patients were non-adherent to the prescribed medications. This poor adherence in asthma is generally either linked to underuse of inhaled steroids or improper inhalation techniques, both of which are associated with poor asthma control.²⁰ Apart from medication, it is of paramount importance that patients must understand what triggers asthma, how to avoid such triggers, and what to do in the case of an acute attack. In the US, the National Asthma Education and Prevention program has made formal patient education a mandatory component integrated in all kinds of asthma care programs. Thus, proper education and counseling of patients about the disease, medicines, and devices can lead asthmatics to enjoy a better QoL, and may reduce the burden of preventable emergency visits and deaths.²¹

Research question

The research was guided by a specific research question: “What is the impact of collaborative CP-GP interventions on clinical, humanistic, and economical outcomes in asthma patients? ”

Rationale of this systematic review

Previous systematic reviews had evaluated the role of CPs in asthma management. However, many of them were not conclusive due to the lack of quantitative synthesis (meta-analysis) of the outcomes,^{10,19,21,22} while other reviews mix a different healthcare setting (hospital, or clinics, or community pharmacy), and thus lack specificity for

community pharmacist,^{10,22–24} nevertheless one review focused on only one outcome, ie, adherence and attempted meta-analysis but again used A mixed setting and does not focus on collaboration.²⁴

There is limited evidence documented in the literature for the effectiveness of CP-GP collaborative approach in asthma management in primary care.²⁵ It is not known whether these interventions have positive, negative, or no effect on patient outcomes. Furthermore, to enrich the understanding of the effectiveness of an intervention, it has been a bench mark in scientific queries to encompass a multidimensional or holistic view of outcomes of an intervention for instance, humanistic or economic outcomes, rather than just focusing on therapeutic outcome. Hence, these rationales and gaps in the evidence necessitate a systematic review focused on CP-GP collaborative intervention for asthma management in terms of clinical, humanistic, and economical outcomes.

The present review takes an account of all three outcomes: clinical, humanistic, and economic, and, thus, has wide outcome coverage, yet, is specific to pool up the contribution of only community pharmacist intervention which were conducted in collaboration with GPs. It has attempted to quantitatively combine data where it was combinable for each outcome in the form of meta-analysis. It is pertinent to mention the essential difference we want to clarify here is the distinction of the interventions as “collaborative” as compared to those where there is no collaboration (interventions administered solo, ie, independent of other healthcare provider), for example, smoking cessations programs offered through community pharmacy or asthma clinic run by independent pharmacists, because, sooner or later, these solo (independent) modes would proffer similar problems (lack of time for proper patient education and counseling, no peer review process of prescriptions) as reported by the critiques of physician’s solo mode of care delivery, since GPs have been engaged independently in healthcare delivery for ages.

To date, there is no study, to our knowledge, that has systematically reviewed the outcomes of collaborative practice between GPs and CPs in the management of asthma. This expanded role of CPs and its collaboration with GPs needs an objective analysis that could lead to evidence which may sum up clinical, humanistic, or economic benefits these collaborative practices may bring. Hence, the focus of this systematic review is asthma management strategies, which involve CPs interventions in collaboration with GPs. The aim of this systematic

review is to summarize the evidence regarding the impact of collaborative care provided by CP-GP in management of asthma. Based on the findings of this review, our objective is to relate and connect various insights to put forward some recommendations to inform the policymakers about the impact of this collaborative care in the management of asthma. Consequently, this evidence base would be placed in the context of the Malaysian healthcare system to explore a number of evidence-based policy options.

Methods

Protocol

The protocol for this review was registered on the “International Prospective Register of Systematic Reviews” (record CRD42017057188). This systematic review was reported in accordance with the PRISMA guidelines.²⁶ Thus, the research question was broken up into Population, Intervention, Outcome, Timings, and Settings (PICO-TS), in Table 1, explaining the pre-defined inclusion and exclusion criteria in detail. The review team ensures the validity of the systematic review, where NM was the main reviewer, CSZ the supervisor, EH the co-supervisor, and TMK an expert of meta-analysis.

Search strategy

Articles were located in 10 databases: NLM PubMed, Medline/Ovid, Cumulative index to Nursing and Allied Health Literature (CINAHL), Scopus, Web of Science, Cochran central register of controlled trials, PsycARTICLES®, Science Direct, Education Resource Information Centre, and PRO-Quest, from inception to January 1, 2017 using the search terms and Medical Subject Heading (MeSH) determined prior to the study using input from experience researchers, librarians, databases specific thesaurus, keywords, and MeSH used in relevant literature. Examples of search terms and MeSH used were: “pharmacist”, “community pharmacy”, “retail pharmacy”, “general physician”, “general practitioner”, “medicine use review”, “drug use review”, and “medication therapy management”. Search terms were constructed in accordance with the PICO model to build a fully fledged search strategy. As databases have differences in terms of search operations and MeSH words, so we tailored our main search strategy as per the requirements of an individual database. Full keywords and MeSH used for locating relevant articles in different databases are available in Appendix I. Boolean logic, wildcards, truncations,

Table 1 Detailed exclusion inclusion criterion as per PICO-TS

	Population	Intervention	Comparator	Outcome	Timings:	Setting	Types of studies
Inclusion	1. Community pharmacist 2. General physician or general practitioner or family physician or family practitioner (in primary care) 3. Asthma out-patients of any age range & gender (both pediatric and adult) and any severity level	All interventions where there is any form of collaboration, whether remote or integrated; between GP/CP, including face to face, telephonic, text, Fax, letter; or email, or any other way of communication, which may involve: 1. All types of medicine use reviews including medication therapy management services 2. Adherence improvement services 3. Counseling 4. Patient Education	No collaboration or usual care.	Primary Outcome: Clinical (asthma severity, asthma control, pulmonary functions, drug use, inhalation technique) Secondary: 1. Humanistic (QoL, adherence, asthma knowledge, hospital or emergency department visits) 2. Economical (cost utility or cost benefit ratio). Report at least one of the outcomes given.	Interventions administered once or frequently	1. Generally, any setting which involves community or retail pharmacist, thus: 2. Community/retail pharmacy collaboratively working with: 1. Primary care 2. GPs clinic (out patients) 3. Nursing homes 4. General practice 5. Family practice 6. Managed care homes *It also includes: The small pharmacy shops with a registered pharmacist integrated within primary care setting. ** It also includes home medication reviews performed by CPs which involve CP-GP collaboration.	Types of studies: Any analytical design involving human 1. Randomized controlled trials, RCT (either randomized pharmacist; physician, or patient) Clustered RCT quasi-experimental, and pre-post intervention study 2. Non-randomized control trials 3. Retrospective observational studies 4. Prospective cohort 5. Pilot studies & Nature of the study: 1. Language: English 2. If a study combines both COPD and Asthma, it will be included only if the outcomes are clearly separable 3. Dissertations

(Continued)

Table 1 (Continued).

	Population	Intervention	Comparator	Outcome	Timings:	Setting	Types of studies
Exclusion	<ol style="list-style-type: none"> 1. Pharmacist assistant involved 2. Nurses & pharmacist collaboration 3. Student pharmacist 4. In-patients 	<ol style="list-style-type: none"> 1. Not clearly reporting about the collaboration in the whole of the study 2. Interventions delivered through pharmacy assistants or students/internee 	—	<ol style="list-style-type: none"> 1. Qualitative outcomes, such as perception, attitude. 2. If study purely evaluates economic outcomes without any GP-CP collaboration 3. Process outcomes, such as number of medication problems identified, or number of recommendations accepted by the GP 		<ol style="list-style-type: none"> 1. Tertiary hospitals 2. Pharmacies in hospitals 3. Schools/College/universities 4. Pharmacist managed independent ambulatory clinics. 	<ol style="list-style-type: none"> 1. Editorials & letter to editor Review articles 1. Non-English language article 2. Not reporting CP intervention 3. Exploring the attitudes and behaviors or perception of pharmacists or physicians or patients. 1. Meetings proceedings (abstracts) 2. Descriptive studies or qualitative research

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; CP, community pharmacist; GP, general practitioner; PICO-TS, Population, Intervention, Comparator, Outcome, Timings and Setting; QoL, Quality-of-Life; RCT, randomized controlled trial.

quotation marks, and proximity operators were used where applicable to reach an appropriate number of hits. A hand search of potentially relevant articles was then executed using the reference lists of relevant studies.

Study selection

Studies were identified through the search in electronic databases, grey literature search, and reference list of relevant articles. The retrieved articles were then de-duplicated in Endnotes, based on inclusion/exclusion criteria, and were subjected to title and abstract screening for eligibility for full text review by NM and checked by CSZ and EH. Whenever there was a doubt on the eligibility of an abstract, its full text was consulted. To be eligible, a study needs to have reported:

- (a) An intervention performed by CPs for asthma management.
- (b) Some degree of collaboration with a GP.
- (c) Either a control group or pre–post research design.
- (d) At least one of the three patient outcomes (clinical, humanistic, economical).
- (e) Be in English language and not a conference proceeding.

Although randomized controlled trials (RCTs) are taken as gold standard in evidence synthesis, it is also a valid assumption to consider that RCT design is not feasible in all situations, so we added controlled trials without randomization as well as other quasi experimental research designs. A study was included if it complied with the pre-set inclusion and exclusion criteria. The examples of collaborative intervention include patient referral, prescription review, education, and counseling, where the comparator was usual care (where no CP/GP collaboration is involved) in a setting which involved community pharmacy and primary care. Detailed inclusion/exclusion criteria are outlined in [Table 1](#). To ensure the validity of the screening process, all excluded articles were reviewed by all authors. In the case of any disagreement on a study for inclusion or exclusion; resolution was achieved through consensus. In the case of any doubt on the nature of collaboration, the corresponding authors were contacted via email to get the larger picture. This was then followed by data extraction of important information and analysis.

Data extraction

Full text studies were duly reviewed, and data were extracted by two members (NM and CSZ) independently to minimize the bias, using a common standardized template for data extraction. This template had columns to add: study characteristics, type of intervention (education, counseling, medicine use review, referral to GPs, inhalation technique improvements, medication adherence assessment, and asthma control), mode of intervention to the patients (face-to-face or through any mail mode), and nature of collaboration between CPs and GPs based on a hypothetical collaboration scale. Any difference between the two members in extracted data was identified and resolved through consensus. Throughout the process of data extraction, we trusted only the data published in the article.

Outcome of interest

Primary outcomes (clinical) include pulmonary functions (peak expiratory flow rate (PEFR), forced expiratory volume 1 (FEV₁), FEV₁/forced vital capacity (FVC), inhalation technique, asthma control, and drug usage. Secondary outcomes include reported results on humanistic outcomes, such as QoL, asthma knowledge, and economic outcomes, for example cost–benefit ratio.

Collaboration scale

The authors designed an arbitrary hypothetical collaboration scale to subjectively evaluate the level of collaboration involved in the included studies. Studies were ranked in terms of the nature of collaborative practice involved. If a study mentioned training of CPs on the management of asthma by the GP or vice versa it had 1 point. On the other hand, if a study mentioned patient referral from GP to CP or vice versa, it was given 2 points; while, a study which highlighted the fact that CPs updated GPs about patient drug usage patterns or diseases state had 3 points and, finally, a study which stated that CPs had a role which allowed them to suggest change of drug or dose and GPs accepted the recommendation was given 4 points on the collaboration scale (the highest score). The maximum points a study could achieve on the collaboration scale were 10 (ie, if the study had reported all four forms of collaboration), where higher scores represent a higher level of collaboration. The collaboration was termed “integrated” if the GPs and CPs share the same premises or “remote” if they do not share the same premises and communicate via phone or emails.

Data analysis

Cochrane Review Manager (RevMan)[®] V.5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used for data analysis.

Risk of bias (RoB) assessment

RevMan was used to generate the ROB graphically. We used different RoB tools for different research designs to appraise RoB in various studies. For instance, (RCT), Controlled trials (CT), and Cluster randomized control trials (C-RCT) were evaluated through the “Cochrane risk of bias tool” because it is a validated tool for RCTs. However, the number of RCTs are limited, and thus allow addition of other research designs for which another tool by Cochrane, “Effective Practice and Organization of Care (EPOC)” was deployed for all non-randomized, or other quasi experimental study designs (pre-post). In EPOC, the studies were evaluated against eight main domains: selection bias (randomization, concealment, baseline measures), baseline outcome difference, attrition bias, detection bias, contamination bias, and reporting bias. As per risk of bias domains, the studies were scored using low, high, and unclear risk. However, it is not encouraged to give some numerical value to the RoB, as per the new Cochrane guidelines, which focus on the domain-based analysis of the RoB in the included studies.²⁷

Procedure of meta-analysis

For meta-analysis, we grouped studies based on outcome and, where at least two studies report combinable data for a specific outcome, meta-analysis was carried out to pool the results. Thus, we performed independent meta-analysis for individual outcomes (n=14) contrasting CP-GP collaborator intervention vs usual care or no care.

As the inclusion criterion for study designs was general and allowed all types of research designs, the studies included in quantitative synthesis were partly different in terms of research designs and tools to measure outcomes. Thus, we combined the data, where it was possibly combinable and aided our findings through both; narrative synthesis (descriptive), as well as through meta-analysis. Only studies were pooled which have reported data in terms of mean and standard deviations (SDs) or in a form which can be convertible to mean or SD through some statistical operation. To compute effect size, standard mean difference was used for continuous variables, while

odds ratio was used for categorical variables. Finally, to synthesize the summary effect estimate of CP-GP collaborative intervention, Forest plots were constructed based on the assumption of random effect model to pool the data for all outcome. A random effect model was deployed because it introspects various sources of variability or heterogeneity, ie, within and in between study variability due to sample size, research design, or tool used to measure the outcome of all the included studies. This is opposite of the fixed effect model, which only takes an account of the statistical heterogeneity among the included studies in meta-analysis. Furthermore, the random effect model yields a conservative effect size rather than an exaggerated one and, thus, does not produce false positive results.²⁸ Three important considerations were taken into account before concluding a meta-analysis.

Heterogeneity

The most common misleading and malpractice while reporting meta-analysis is pooling of data when there is considerable heterogeneity, which gave rise to false conclusions.^{29–33} Thus, heterogeneity is a decisive factor to authorize whether the data in various studies are combinable or not. τ^2 or χ^2 and I^2 are some of the tests used to determine statistical heterogeneity, but the I^2 does not suffer from some of the drawbacks of the other two tests, and thus holds more reliability.²⁹ I^2 is the percentage of total variance. I^2 values of 25%, 50%, and 75% indicate low, moderate, and high heterogeneity, respectively.³⁰ Thus, heterogeneity in the included studies in meta-analysis was accessed through I^2 statistic, where a higher value of I^2 means a higher level of variability because of factors other than random variations. An I^2 value of zero or less than 25% gives credibility that the effect size produced by pooling of data of various studies represents the true value of a homogenous population (ie, the studies don't have different populations), and there is no need of subgroup or sensitivity analysis.^{30,34,35} On the other hand, high I^2 value indicates that the populations across different studies in a meta-analysis are different, hence pooling of data makes no sense and should be avoided. In this case the next step is to perform a subgroup analysis to determine any valid reason of heterogeneity, if the heterogeneity value get insignificant in a subgroup analysis, then the pooled effect size of an intervention holds much credibility than the overall analysis. In our case, if $I^2 > 25\%$, we preferred to perform subgroup analysis based on research designs to get a subgroup which has low I^2 values and

may allow the pooling of data to draw valid results. Zlowodzki et al,³⁶ suggested to determine the reasons of heterogeneity through subgroup analysis under a pre-defined criterion, and this review followed the guidelines provided for subgroup analysis.³⁷

Effect size (ES)

“Effect” is a measure of association between an intervention or exposure and an outcome. Effect size is the magnitude or strength of the association, and is represented by “d”, also called “Cohen’s d”. The beneficial or non-beneficial results of meta-analysis are indicated by effect size.³⁸ Medical researchers are often interested to establish the superiority of one intervention over another. They do it by computing the difference between the intervention and control group.³⁹

Interpretation of ES

As per Cohen’s classification, an ES of magnitude 0.2, 0.5, and 0.8 denotes small, medium, and large ES, respectively.⁴⁰ The effect size value may be positive or negative. For continuous outcomes, an ES of zero means there is no difference between the groups being compared, while, for binary outcomes the value of 1 would indicate there is no difference between the groups. ES has been discussed in details by Durlak,⁴⁰ and throughout our meta-analysis we will stick to the interpretations and guidelines provided.^{40,41}

Results

After a careful title and abstract screening, 8,604 studies were excluded and 84 studies were examined in full text. Only 23 out of 84 studies were found at par with all the inclusion/exclusion criteria, while studies were excluded in full text screening because of different settings (n=13), studies did not mention any level of CP-GP collaboration (n=33), outcomes were not of interest (n=10) or combined both chronic obstructive pulmonary disease and asthma (n=1), an ongoing study, ie, study protocols (n=3), and a descriptive study (n=1).

A total of 23 articles were included in the final review (Figure 1). There were six studies with RCT study designs, four C-RCT, three controlled interventions (CI), seven pre-post (PP) studies, and three case control studies (CC). Most of the studies were conducted in Australia (n=8); followed by the US (n=3); UK, Germany, Canada (n=2 each), and Finland, Spain, Italy, Malta, Denmark, and Belgium (n=1 each).

There was a wide range of patient’s age included in this review; age ≥ 18 years (n=18), age ≥ 12 years (n=4), and age ≥ 7 years (n=1). The majority of the studies provided interventions to patients with moderate-to-severe asthma. The duration of the studies included in this review ranged from 6 weeks to 5 years; 6 weeks (n=1), 3 months (n=1), 6 months (n=11), 9 months (n=2), 12 months (n=7), and 5 years (n=1). The most common mode of delivery of the asthma intervention was face to face (n=19), followed by “mailed intervention” (n=3). One study compared “mail vs face to face intervention”, and one study used mix mode intervention ie, face to face and mail follow-up.

Seven studies reported the duration of the intervention provided by CPs per session. The duration of intervention, categorized by the researchers, was divided into: 10–30 minutes (n=5), 31–44 minutes (n=1), and 45–60 minutes (n=1). There was little information available on the duration of intervention in other studies (n=15).

Furthermore, 14 studies reported the number of visits a patient had to attend CP during the study to receive intervention. The most common number of intended visits cited were four (n=9), but it varies considerably based on the duration of study. As a matter of fact, the shorter the duration of the study the less visits can be possible. The most common type of CPs’ intervention in these visits was patient education and counseling, which focused on: inhaler technique correction (n=10), asthma knowledge (n=11), self-management measures to keep asthma under control (n=9), drug use and therapy monitoring (n=9), and medication adherence (n=8). Nearly all studies employed more than one intervention.

The scores on the hypothetical collaboration scale showed that seven studies obtained scores of 10/10, while one study obtained 9/10 and one study had an 8/10 score. The remaining the studies (n=9) have a score $< 8/10$. “Patient referral” was the most frequent (n=17) type of collaborative intervention cited in the studies, followed by “CP’s training” (n=15), ie, CPs’ training by physician, for a proposed intervention, such as on disease management or pathological basis asthma or how to respond to an emergency. Almost half of the studies (n=11) mentioned the highest form of collaboration, ie, where CPs recommended their GPs for changes in medicine or dose. There was only one study which involved “integrated” collaborative practice between GP and CP, while the rest of the studies (n=22) involved remote collaboration.

A summary of the reported outcomes is provided in Table 2. Based on broad categories of outcomes as defined in the inclusion criteria (clinical, humanistic, and

Figure 1 PRISMA flow diagram.

Abbreviations: COPD, chronic obstructive pulmonary disease; CP, community pharmacist; C-RCT, clustered randomized controlled trial; GP, general practitioner; RCT, randomized controlled trial; Tit/Abs, Title/Abstract; n, number.

economic outcomes), only four studies reported all three outcomes. On the other hand, five studies reported purely clinical outcomes and two studies reported only humanistic outcomes.

Appraisal of risk of bias

Summary graphs of Cochrane risk of bias and EPOC risk of bias are depicted in Figures 2–5, respectively. As an overall finding, the studies included were free of many types of biases. However, the most common bias present was the “blinding of personnel”. However, this is understandable as in this kind of scenario where an educational intervention is administered to improve asthma knowledge or drug use process, blinding of either patient or personnel is not always possible.

Impact of the collaborative interventions

To pool up the results of outcomes, we opted both methods, ie, qualitative or narrative synthesis, as well as quantitative or meta-analysis by statistically combining (where possible) the results to produce a summary effect of individual outcomes.

Evidence base through narrative synthesis

To perform a narrative synthesis, outcomes were grouped into two broad categories:

- Favorable or significant (where the study clearly mentions a *p*-value less than 0.05, indicating significant improvements by CP’s intervention).

Table 2 Summary of the characteristics of the included studies

Author/ year/ country	Study design/ duration	Patients		Population	Description of services	Collaboration		Outcomes		
		Intervention	Control			Type	CS score	Type/measure	Result	p-value
Armour et al, ⁴⁹ 2007, Australia	RCT/6 M Multi- sites=50	165/351	186/351 (UC)	Adult=18–75 years (mild-to- moderate-to- severe asthma)	Face to face (4 compulsory visits, 1 optional). Patient education and coun- selling on: inhaler techniques assess- ment and correction; asthma knowledge, self-management and con- trol; medication adherence assessment and assurance; follow-up 1, 3, 6 M post-baseline; duration of session =NC	RCT	10	Asthma severity/ NAC severity assessment table - severe asthma - moderate asthma - mild asthma	↓ in I act C ↓ in I act C ↑ in I act C	<0.001 <0.001 <0.001
								Pulmonary func- tions/spirometry - FEV ₁ - FEV ₁ /FVC	-NSSD b/w I and C -NSSD b/w I and C	=0.14 =0.71
								Inhalation techni- que correction/ I act C DSC	Improved in I act C	<0.001
								Adherence/BMQ	↑ in I act C	=0.04
								QoL/AQLQ score	↑ in I act C	=0.05
								Asthma knowl- edge/CAKQ score	↑ in I act C	<0.01
Asthma control (perceived)/PDAQ score	↑ in I act C	<0.01								

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients			Description of services	Collaboration		Outcomes		
		Intervention	Control	Population		Type	CS score	Type/measure	Result	p-value
Armour et al, ⁴⁷ 2013, Australia	C-RCT/6 M	3 visits =193/ 354	4 visits = 161/354 *3 vs 4 visits act as con- trol for each other.	Adult=18 years or > (severe asthma Pt at risk of adverse events)	Face to face (3 and 4 compulsory vis- its). Patient education and counseling on: inhaler techniques assessment and correction; asthma knowledge and self-management; drug use and therapy monitoring; medication adherence assessment and assurance; follow-up 12 M post baseline; median time/dura- tion of session for visit 1, 2, 3, 4 were 75, 30, 50, 20 minutes, respectively; median duration 20 minutes	RCT	10	LABA usage	Almost equal ↑ in both groups.	<0.05
								Corticosteroid usage	Almost equal ↑ in both groups	<0.05
								SABA usage	Almost equal ↓ in both groups	<0.001
								Inhalation techni- que correction/ DSC	Almost equally improved in both groups	<0.001
								Adherence/BMQ score	Almost equal ↓ in both groups	<0.01
								QoL/AQLQ score	Almost equally improved in both groups	<0.001
								Asthma control (perceived)/ (PACQ)	Improved in both groups	<0.001
								Asthma knowl- edge/CAKQ score	Groups but 4V more improved act 3 visit Almost equally improved in both groups	<0.001

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients			Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention		Type	CS score	Type/measure	Result	p-value
Garcia-Cardenas et al, ⁵ 2013, Spain	C-RCT/6 M	186/336	150/336 (UC)	Adult=18 years or > (patients with moderate to severe asthma)	Face to face (3 compulsory and 3 optional visits only if needed). Patient education and counseling on: inhaler techniques assessment and correction; asthma knowledge and self-management; medication adherence assessment and assurance; follow-up 3, 6 M post baseline; duration of session =NC		RCT	I	Inhalation technique correction/ DSC	Improved in I act C	<0.001
									Adherence/MMAS	↑ in I act C	<0.001
									Asthma control/ mean ACQ	↓ in I act C (improved control)	<0.001
Manfrin et al, ⁴³ 2017, Italy	C-RCT/ 9 M (largest RCT conducted in community pharmacy for asthma in the world)	400/816	416/816 (UC)	Adult=18 years or > (general asthmatic population)	Face to face (number of visits =NC). Medicine use review Education on assessment of: asthma severity and control; medication adherence; duration of session =26 minutes; follow-up 6, 9 M post baseline NOTE: Two groups A and B. A started the intervention soon after training while B started execution of intervention 3 months later.		RCT	10	Asthma control/ ACT	↑ in I act C	<0.01
									Adherence/MMAS	↑ in I act C	<0.01
									Cost effectiveness analysis/cost per QALY	Cost effective in I act C	<0.01
									QoL/QALY/ EuroQol-5D:	↑ in I act C	=0.01

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients		Description of services	Collaboration		Outcomes		
		Intervention	Control		Type	CS score	Type/measure	Result	p-value
McLean et al, ⁵³ 2003, Canada	C-RCT/12 M	191/450	226/450 105/450 *3 arms study, 1 intervention and 2 con- trol group (UC)	Adult/pediatric mix: 7–84 years (uncontrolled asthma Pt OR severe)	RCT	4	PEFR	↑ in I act C	≈0.0002
							Asthma symptoms/ total symptom score	↓ in I act C	≈0.000
							SABA usage	↓ in I act C	≈0.0082
							Corticosteroid usage	NSSD	≈0.6309
							Asthma knowl- edge/21 item questionnaire	↑ in I act C	≈0.000
							QoL/AQLQ-J	Improved in I act C	≈0.0001
							ED visits	NSSD	≈0.4757
							Hospital visit	NSSD	≈0.939
							Asthma control	Improved in I act C	≈0.005

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients			Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention		Type	CS score	Type/measure	Result	p-value
Mehuys et al, ⁵¹ 2008, Belgium	RCT parallel- group/ 6 M	80/150	70/150 (UC)	Adult=18-50 years (moderate-to- severe asth- matics on a controller or maintenance medication)	Face to face (5 visits) Patient education and counseling on: inhaler techniques assessment and correction; asthma knowledge and control; medication adherence assessment and assurance; drug use and therapy monitoring; duration of session =NC; 1, 3, 6 M follow-up post baseline		RCT	5	Asthma symptom Nighttime awakenings Need for rescue medication/(SABA usage) Inhalation techni- que correction/ I act C DSC Adherence/refill rates and self- reporting Asthma control/ ACT score QoL/AQLQ, score ED visits or hospitalizations Asthma knowl- edge/KAAMQ, PEF	NSSD NSSD Improved in I act C NSSD NSSD NSSD NSSD NSSD	=0.044 =0.044 =0.004 =0.016 =0.492 =0.128 NC =0.133 =0.703
Bereznicki et al, ⁵⁸ 2013, Australia	RCT/ 6 weeks	Mail = 414/1,083	Face to face =235/1,083 Control =434/1,083 (UC)	Adult=18 years or > (general asth- matic population)	Face to face vs mail vs control Patient education and counseling on: asthma medications, management and control; drug use and therapy monitoring; analysis of poor asthma control from drug dispensing data and its manage- ment; duration of session =NC		RCT	6	Preventive-to- reliever drug ratio Daily SABA use Daily corticoster- oid usage	↑ in F> Ma > C ↓ in F> Ma > C ↓ in Ma act C ↑ in F act M and C	<0.0001 <0.0001 =0.48 =0.14

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients		Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention	Type	CS score	Type/measure	Result	p-value
Charrois et al, ⁴² 2006, Canada	RCT/ 6 M	29/61	32/61 (UC)	Adult=17–54 years (Pt with poorly controlled asthma/high risk Pt)	Face to face (4 visits) Patient education and counseling on: inhaler techniques assessment and correction; asthma control; medication use assessment; follow-up, 2 weeks, 1, 2, 4, 6 M; duration of session =NC	RCT	3	Oral steroid use	NSSD	=0.11
								Inhaled steroid use	NSSD	=0.51
								FEV ₁	NSSD	=0.40
								Asthma control/ ACQ score	NSSD	=0.91
								ED or hospital visit	NSSD	=0.91
								Inhalation techni- que correction/ DSC	Improved in I act C	=0.04
Cordina et al, ⁵⁰ 2001, Malta	RCT/ 12 M	64/119	55/119 (UC)	Adult=14 years or > (general asth- matic population)	Face to face (12 visits) Patient education and counseling on: inhaler techniques assessment and correction; asthma symptom control; duration of session =NC; follow-up 4, 8, 12 M post baseline	RCT	10	Inhalation techni- que correction/ DSC	Improved in I act C	=0.021
								PEF	↑ in I act C	>0.05
								Asthma symptoms (night wheeze)	Improved in I act C	=0.051
								QoL/LWAQ	Improved in I act C	=0.044
Barbanel et al, ⁵⁷ 2003, UK	RCT/ 3 M	12/24	11/24 (UC)	Adult=18–65 years (general asth- matic population)	Face to face (number of visits =NC) Patient education and counseling on: asthma self- management; symptoms monitoring, recognition of trigger, emergency access; duration of session =45–60 minutes; follow-up by phone	RCT	1	Self-reported hospitalization	↓ in I act C	>0.05
								Asthma symptoms/ NEASS score	↓ in I act C	<0.001

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients			Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention		Type	CS score	Type/measure	Result	p-value
Crowder, ⁴⁴ 2000, USA	Pre-post (Quasi experi- mental) two control groups/ 6 M	6/12	6/12 an external control group=81	12 years or > (general asth- matic popula- tion who has Oregon Health Plan)	Face to face (8 visits) Patient education and counseling on: asthma knowledge; asthma, self- management, monitoring, recognition of trigger, emergency handling; medicine use review; duration of session = 10–30 minutes; follow-up 6M		RCT	10	QoL/LWAQ score	NSSD	=0.9330
									Asthma knowl- edge/patient asthma IQ form	NSSD	=0.0220
									Cost-benefit analy- sis - GP office visit cost - hospital visit cost - ER visits costs - beta agonist and inhaled corticos- teroid cost	↓ post inter- vention ↓ post inter- vention ↓ post inter- vention NSSD post intervention	<0.0424 <0.0001 =0.0273
									Cost benefit ratio	(\$5.71 returned for every \$1.00 invested)	NA

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients		Description of services	Collaboration		Outcomes		
		Intervention	Control		Type	CS score	Type/measure	Result	p-value
Bunting and Cranor; ⁴⁵ 2006, USA	Pre-post (Quasi-experi- mental, longitu- dinal)/5 years	202	NA	Face to face (4 visit/year) Patient education and counseling on: asthma knowledge and control; medication adherence assessment and assurance; drug therapy assessment and management; self-management and monitoring of symptoms; duration of session ≈30 minutes; follow-up=annual	RCT	10	Asthma symptoms: wheezing episodes, cough/wheezing after allergen exposure, cough- ing, chest tight- ness/pain, exacerbation, nighttime awakening	↓ post intervention	<0.0008
								↓ post inter- vention	≈0.0011
								↓ post intervention	≈0.01
							FEV ₁	↑ post intervention	<0.00001
							QoL/AOMS score	All improved post intervention	<0.01
							Asthma severity (categorized as severe or moder- ate, persistent)	↓ post intervention	<0.0008
							ED visits	↓ post inter- vention 16.9 to 1.9 visits/ 100 pts/year	NC
							Hospital admissions	↓ post inter- vention from 5.1 to 1.9/ 100 pts/year	NC

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients			Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention		Type	CS score	Type/measure	Result	p-value
Gums et al, ¹⁵ 2014, USA	Pre-post (inter- ventional)/ 9 M	93	NA	12–83 years (Pt with persis- tent asthma)	Face to face (4 visits) Patient education and counseling on: asthma self-management and control; medication adherence assessment and assurance; drug use and therapy monitoring; duration of session = mean 60 minutes, for baseline and 15–20 minutes after- wards; follow-up = 1, 2, 4, 6, 9 M post baseline (3, 5, 7, 8 M and 2 weeks call optional for poor asthma control pt)	I		10	Final trends over 5 years: - direct cost sav- ing/5 years - Indirect cost sav- ing - Combined direct and indirect sav- ings/5 years	\$161,187/pt/ year \$1,230/pt/ year \$584,307	NA
									Number of ED visits and/or hospitalizations	↓ post inter- vention (not sustained)	=0.052
									Adherence/self- reported validated questionnaire	↑ post inter- vention (not sustained)	=0.03
									Asthma control/ ACT mean scores	↑ post inter- vention (sustained)	<0.0001
									QoL: AQLQ-M mean scores	↓ post inter- vention (sustained)	<0.0001
									Inhaled corticos- teroids use	↑ post inter- vention (sustained)	=0.024
									SABA use	NSSD	NC
									LABA use	NSSD	NC

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients			Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention		Type	CS score	Type/measure	Result	p-value
Mangiapan et al, ⁵² 2005, Germany	Pre-post (inter- ventional)/1 year	128	NA	Adult=18–65 years (general asth- matic population)	Face to face (5 visits) Patient education and counseling on: inhaler techniques assessment and correction; asthma control and symptom manage- ment; medication adherence assess- ment and assurance; duration of session =NC; follow-up =6, 12 M post-baseline		RCT	5	Asthma symptoms/ by patients	↓ post intervention	<0.001
									Asthma severity	↓ post intervention	<0.002
									PEFR	↑ post intervention	<0.001
									FEV ₁	NSSD	=0.48
									Adherence/MMAS	↑ post intervention	<0.001
Narhi et al, ⁵⁹ 2000, Finland	Pre-post (inter- ventional)/ 1-year interven- tion, 1-year fol- low-up	28	NA	Adult=20–64 years, (asthmatics with mismanage or uncontrolled asthma)	Face to face (4 visits) Patient education and counseling on: asthma symptoms; drug use and therapy monitoring; duration of session =NC; follow-up =after 1 year		RCT	8	Inhalation techni- que correction/ DSC	Improved post intervention	<0.001
									QoL - LWAQ score	↑ in post intervention	<0.001
									Asthma knowl- edge/AKQ	↑ in post intervention	<0.001
									Asthma symptoms: daytime wheeze, mucus excretion and allergic symp- toms; night time wheeze and night time cough	↓ post inter- vention ↓ post inter- vention (both sus- tained at 24 minute fol- low-up) NSSD	<0.001 =0.02 >0.05
									Oral steroid usage	↓ post intervention	NC

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients		Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention	Type	CS score	Type/measure	Result	p-value
Saini et al, ⁶⁰ 2011, Australia	Pre-post (inter- ventional) 6 M	3 visits = 216/ 398 4 visits = 182/ 398	NA	Adult = 18 years or > (general asth- matic population)	Face to face (3–4 visits) Education and counseling on: asthma knowledge; duration of session = NC; follow-up = after 6, 12 M (mail ques- tionnaire for follow-up)	RCT	1	Asthma knowl- edge: CAKQ	↑ post inter- vention in both groups (3 visits & 4 visits; how- ever, NSSD between the groups. (sustained by 12 M follow- up)	<0.001
Grainger- Rousseau et al, ⁶¹ 1997, UK	Clinical con- trolled inter- vention 6 M	50/98	48/98	Age range not clear; mean age = 16.8 (general asth- matic population)	Face to face (4 visits) Patient education and counseling on: inhaler techniques assessment and correction; drug use and therapy monitoring; asthma symptoms management; duration of session = NC; follow-up = NC	RCT	5	Inhalation techni- que correction/ DSC	Improved post intervention	<0.05
								PEFR and night time wheeze	Improved post intervention	<0.05
								Asthma symptoms (patient reported) and night time cough, day time wheeze	NSSD	>0.05
								FEV ₁ : FVC	NSSD	>0.05
								QoL/QWB	Not improved post intervention	>0.05
								Hospitalization	NSSD	>0.05

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients		Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention	Type	CS score	Type/measure	Result	p-value
Herborg et al, ⁶² 2001, Denmark	Clinical controlled inter- vention multi- center/12 M	209/413	204/413 (UC)	Adult=16-60 years (moderate-to- severe asthma)	Face to face (12 visits) Patient education and counseling on: inhaler techniques assessment and correction; asthma symptom management; drug use and therapy monitoring; duration of session =41 minutes; follow-up =NC	RCT	8	Asthma symptom/	↓ in I act C	=0.022
								PEFR	NSSD	=0.064
								Inhalation technique correction/ DSC	Improved in I act C	<0.001
								Asthma knowledge/17 items questionnaire	↑ in I act C	<0.001
								QoL/LWAQ	Improved in I act C Improved in I act C	<0.001
								Hospital admissions and asthma clinic visit.	↓ in I act C	NC
								SABA usage	Apparently decrease in I act C but NSSD	=0.086
								LABA usage	↑ in I act C	=0.019
								Corticosteroid usage	↑ in I act C	=0.018

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients		Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention	Type	CS score	Type/measure	Result	p-value
Schulz et al, ⁵⁶ 2001, Germany	Clinical con- trolled inter- vention/12 M	101/164	63/164 (UC)	Adult=18–65 years (mild to severe asthma)	Face to face (8 visits) Patient education and counseling on: inhaler techniques assessment and correction; asthma knowledge and severity; duration of session =NC; follow-up =6, 12 M	RCT	9	Inhalation techni- que correction/ DSC	improved in I act C	<0.001
								Asthma knowl- edge/asthma knowledge questionnaire	↑ in I act C	<0.001
								QoL/LWAQ	Improved in I act C	=0.018
								Asthma severity (rated by patients)	Improved in I act C	=0.008
								FEV ₁	NSSD	=0.475
								PEFR	NSSD	=0.515

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients		Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention	Type	CS score	Type/measure	Result	p-value
Saini et al, ⁴⁶ 2004, Australia	Clinical controlled intervention repeated measure / 6 M (2 control group)	39/67	28/67 *2 control groups were added to make this number: (UC)	Asthmatics who use bronchodilator medications >3 times a week or with recurrent attacks	Face to face (4 visits) Patient education and counseling on: inhaler techniques assessment and correction; asthma knowledge and control; medication adherence assessment and assurance; asthma medications use monitoring; duration of session =56.6 minutes for baseline, 18.8 minutes 2 nd session and 21.1 minutes/pt 3 rd session; follow-up = 1, 3, 6 M	RCT	5	SABA usage Preventer to reliever ratio LABA/inhaled corticosteroid Adherence/BMQ Asthma severity QoL/AQLQ-M score Asthma control (perceived) Asthma knowledge/31 items questionnaire Annual savings per Pt Cost-savings due to an overall ↓ in severity PEF Hospitalization	↓ in I act C ↓ in I act C ↑ in I act C ↓ in I act C ↓ in I act C Improved in I act C ↑ in I act C ↑ in I act C \$132.84 (in I act C) \$8,400.10/M (in I act C) Improved in I act C Not significant	<0.015 <0.001 <0.008 =0.001 <0.001 <0.001 <0.001 =0.04 NC NC <0.001 =0.08

(Continued)

Table 2 (Continued).

Author/ year/ country	Study design/ duration	Patients		Description of services		Collaboration		Outcomes		
		Intervention	Control	Population	Intervention	Type	CS score	Type/measure	Result	p-value
Bereznicki et al, ⁵⁵ 2008, Australia	Case control/6 M	706/1,133	427/1,133 (UC)	Adult=18 years or > (general asth- matic population)	Mail Dispensing record mining by software to identify patients with suboptimal man- agement of asthma. Patient education and counseling (writ- ten material) on: asthma knowledge, symptoms and con- trol; follow-up =6 M; duration of session =NA	RCT	5	Asthma control/ ACT	↑ in I act C	<0.01
								Asthma knowl- edge/CAKQ	NSSD	=0.41
								QoL/Mini AQLQ score	Improved in I act C	<0.05
Bereznicki et al, ⁶³ 2008, Australia	Case control study/6 M	702/1,551	849/1,551 (UC)	Adult=18 years or > (general asth- matic population)	Mail Dispensing record mining by software to identify patients with suboptimal man- agement of asthma. Patient education and counseling (writ- ten material) on: asthma medication knowledge and appropriate use (drug use and therapy monitoring); follow-up =6 M; duration of session =NA	RCT	5	Preventer-to-relie- ver ratio	↑ in I act C	<0.01
								Preventers ICS (daily usage)	↓ in I act C	<0.001
								SABA (daily usage)	↓ in I act C	<0.001
Bereznicki et al, ^{48,64} 2011, Australia	Case control/ 12–18 M (follow-up study)	421/718	297/718 (UC)	Adult=18 years or > (Pts who are at risk of poor asthma control)	Mail Education by mail on: drug usage; analysis of poor asthma control from drug dispensing data; drug use and therapy monitoring; duration of session =NA	RCT	5	Preventer-to-relie- ver ratio	↑ in I act C (sustained by 18 months)	<0.001
								SABA usage	↓ in I act C	<0.0001
								ICS usage	↑ in I act C	<0.0001

Abbreviations: Pt, patients; DD, daily dose; UC, usual care; M, month; NA, not applicable; CS, collaboration scale; NC, not clear; ED, emergency department; C, control; I, intervention; RCT, randomized controlled trials; C-RCT, clustered randomized controlled trial; PEFR, peak expiratory flow rate; PFI, peak flow index; VC, vital capacity; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; SOB, shortness of breath; NSSD, not statistically significant difference; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality-of-Life Questionnaire-Juniper; AQLQ-M, Asthma Quality-of-Life Questionnaire-Marks; Mini-AQLQ, Mini-Asthma Quality-of-Life Questionnaire; EPR-2, Expert Panel Report-2; LWAQ, Living with Asthma Questionnaire; QWB, Quality of Wellbeing questionnaire; SABA, short-acting beta receptor agonist; BMQ, Brief Medication Questionnaire; MMAS, Morisky medication adherence scale; KAAMQ, knowledge of asthma and asthma medicine questionnaire; AOMIS, Asthma Outcomes Monitoring System; AKQ, Asthma Knowledge Questionnaire; CAKQ, Consumer Asthma Knowledge Questionnaire; PCAQ, Perceived Control of Asthma Questionnaire; CAKQ, Consumer Asthma Knowledge Questionnaire; NHP, Nottingham Health profile; PFM, Peak flow meter; AMI, Asthma Morbidity Index; NEASS, North of England Asthma Symptoms Scale; CR, cluster randomized control trial; P, pre-post study; Cont, controlled clinical intervention; CC, case control study; DSC, Device Specific Checklist; F face to face; Ma, mail; act, as compared to; C, control.

Figure 2 ROB Cochrane graph.

- (b) Unfavorable or non-significant (where the study clearly mentions a p -value more than 0.05, indicating no significant improvements by CP's intervention or no difference between intervention or control group).

The summary of the narrative synthesis of the impact of the CP-GP collaborative interventions on all outcomes are summarized in Table 2 and Figure 6.

Clinical outcomes

Eight studies reported the intervention outcomes on PEFR values from baseline to end-point. Of these, four studies concluded significant differences in improvement in PEFR between the intervention and control groups. However, four studies delineated no significance difference. Similarly, for FEV₁, four out of five studies showed no significant difference made by the intervention. FEV₁/FVC was measured in two studies, both showed non-significant improvements in the intervention as compared to the control group.

Asthma symptoms described as night time or day time wheezing and chest tightness, were evaluated in ten studies. Of these, nine posed significant positive results. Two studies demonstrated mixed results (positive for certain symptoms and not significant for others), and one study concluded no significant change. Nevertheless, the overall impact was positive.

Outcome on asthma severity was reported in five studies. The definition of asthma severity varies across the studies; nevertheless, all studies hold significant impact of interventions.

There were ten studies which explored asthma control as an outcome. Asthma control was defined by a specific

score achieved on instruments deployed to measure the asthma control. These instruments were the Asthma Control Questionnaire (ACQ), Asthma Control Test (ACT), and Perceived Control of Asthma Questionnaire (PCAQ), and one other. Two studies showed non-significant results, as compared to eight significant studies.

A total of nine studies reported SABA usage in asthma patients, where seven hold a significant decrease in SABA usage in the intervention group, while one was non-significant, and one did not provide any conclusive data. Similarly, LABA use was discussed in four studies, three significant and one did not provide the data at end. Corticosteroids use was reported in ten studies; out of these, five were significant, four non-significant, and one study did not report the data. Another important parameter in drug usage in asthma patients was preventer-to-reliever ratio, which was highlighted in four studies, and these studies demonstrated significant improvement in the intervention group. The impact of GPs-CPs collaboration on asthma drug use. Two studies^{15,43} showed mixed results (improvement in one drug used but no change in another anti-asthmatic drug used).

Eleven studies applied educational intervention to the correct inhalation technique. All studies recorded significant improvement in patients' inhalation techniques.

The effects of these interventions on the number of hospital visits were evaluated in nine studies. Three studies mentioned the lack of data to reach any conclusion, while, the six remaining studies, except one, all reported non-significant results. On the other hand, an emergency room visit was an intended outcome in six studies, three studies could not reach to a conclusion because of limited data to perform statistical operation, while two studies documented non-significant results and one held significance.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
B. J. Bereznicki et al., 2013	+	?	+	+	?	+	+
Barbanel et al., 2003	+	?	-	-	+	+	-
C. Armour et al., 2007	+	+	-	+	+	+	+
C. L. Armour et al., 2013	+	+	-	?	+	+	+
Charrois et al., 2006	+	+	-	+	-	+	+
Cordina et al., 2001	+	+	-	-	-	+	+
Garcia-cardenas et al., 2013	+	+	-	?	+	+	+
Manfrin et al., 2017	+	+	-	+	+	+	+
McLean et al., 2003	+	?	+	+	-	+	+
Mehuys et al., 2008	+	+	-	+	+	+	?

Figure 3 ROB Cochrane summary.

Note: +, - and ? show low, high or unclear risk of bias, respectively.

Humanistic outcomes

Other reported outcomes of GPs and CPs collaborative practice in asthma management include assessment of medication adherence, asthma drug use, and improvement in inhalation technique and knowledge of asthma. Eight studies reported medication adherence outcomes, where all of them are significant. In those studies, measurement of medication adherence was done using various tools, such as the Morisky medication adherence scale (MMAS) (n=3), Brief Medication Questionnaire (BMQ) (n=3), and the remaining two used self-reported questionnaires.

Patients' knowledge on asthma was assessed in 11 studies. Nine studies showed significant improvement on patients' asthma knowledge and medicine used in the asthma after intervention. This improved knowledge made patients better control and manage asthma. Only two studies reported non-significant changes. There is a considerable variation in the instruments used to measure asthma knowledge reported in those studies. Still, four studies used the Consumer asthma knowledge questionnaire (CAKQ), and three studies deployed the Asthma knowledge questionnaire (AKQ), while all other studies

Figure 4 EPOC graph.

used different instruments (21-item questionnaires, Knowledge of asthma, and asthma medicine questionnaire).

Fifteen studies reported the impact of GPs-CPs collaborative practice on patients QoL. Of these, 12 studies reported significant improvement in QoL in the intervention group, while no significant difference between the groups was reported in three studies. Five studies used the Living with Asthma Questionnaire (LWAQ) as a tool to measure QoL, while seven studies administered various forms of the Asthma Quality-of-Life Questionnaire (AQLQ: AQLQ-J, AQLQ-M, AQLQ-mini, AQLQ, IAQLQ), and three studies incorporated others.

Economic outcomes

Economic outcomes were only reported in five studies. All five studies mentioned value for money of the collaborative practices in various study designs. The most recent national level study in Italy is the most promising one, where cost-effectiveness analysis (the difference in costs from the public healthcare and society perspectives) by the end of study proved the hypothesis that CPs' provided interventions were more cost-effective than usual care, and the probability of being cost-effective increased from 51.50% at 3 months to 100% at 9 months.⁴³ Another study⁴⁴ cited a cost benefit ratio of CP's interventions as \$5.71 returned for every \$1.00 invested as compared to usual care. Similarly, the largest study in the US demonstrated the financial trends in the sense of a direct cost saving of \$1,61,187/pt./Y and an indirect cost saving of

\$1,230/pt./Y of these interventions.⁴⁵ Finally, a study in Australia concluded annual savings per patient Australian \$132.84, but *p*-values were not mentioned.⁴⁶

Evidence base through meta-analysis

The step by step procedure and results of all meta-analyses of each outcome are presented in Tables 3 and 4, while larger high definition images of meta-analyses are also provided in Appendix II. Out of 14, 11 outcomes were concluded in favor of CP-GP collaborative interventions with different magnitude of ES. Eight outcomes (Asthma Severity, Asthma Control, Asthma symptoms, PEFR, SABA Usage, Hospital visit, Adherence and QoL (AQLQ, LWAQ)) demonstrated a small ES ($d \geq 0.2$), three outcomes (Inhalation Technique, ED visit, and Asthma Knowledge) witnessed medium ES ($d \geq 0.5$). Inhalation technique yielded large ES ($d \geq 0.8$) in RCTs subgroup analysis. However, three outcomes (FEV₁, Corticosteroids usage, and Preventer to Reliever ratio) did not hold significant ES ($d < 0.2$) and, thus, remain inconclusive. The collaboration was shown to be value for money in the economic studies in narrative synthesis; however, a limited number of studies did not allow pooling of data in meta-analysis. For all outcomes, the conclusion based on effect size is summarized in Table 5.

Discussion

To our knowledge, this is the first review and meta-analysis of CP-GP collaborative intervention in asthma management. The evidence base from this systematic review witnessed the increasing level of collaboration between CPs and GPs, and

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Baseline outcome measurement	Baseline characteristics	Incomplete outcome data (attrition bias)	Blinding of participants and personnel (performance bias)	Study protected against contamination	Selective reporting (reporting bias)	Other bias
B. J. Bereznicki et al., 2013	+	?	+	+	?	+	+	+	+
Bandana Siani et al., 2004	+	?	+	+	+	+	+	+	?
Bandana Siani et al., 2011	?	?	+	+	+	+	+	+	+
Barbanel et al., 2003	+	?	+	+	+	+	+	+	+
Bunting & Cranor, 2006	+	?	+	+	+	+	+	+	+
C. Armour et al., 2007	+	+	+	+	+	+	+	+	+
C. L. Armour et al., 2013	+	+	+	+	+	+	+	+	+
Charrois et al., 2006	+	+	+	+	+	+	+	+	+
Cordina et al., 2001	+	+	+	+	+	+	+	+	+
Crowder, 2000	+	?	+	+	+	?	?	+	?
Garcia- cardenas et al., 2013	+	+	+	+	+	+	+	+	+
Grainger rousseau et al., 1997	?	?	+	+	+	+	+	+	+
Gums et al., 2014	+	+	+	+	+	+	+	+	+
Herborg et al., 2001	+	+	+	+	+	+	+	+	+
Manfrin et al., 2017	+	+	+	+	+	+	+	+	+
Mangiapane et al., 2005	?	?	+	+	+	+	+	?	?
McLean et al., 2003	+	?	+	+	+	+	+	+	+
Mehuys et al., 2008	+	+	+	+	+	+	+	+	?
Narhi et al., 2000	?	?	+	+	+	+	+	+	?
Schulz et al., 2001	+	?	+	+	+	+	+	+	+

Figure 5 EPOC summary.

Note: +, - and ? show low, high or unclear risk of bias, respectively.

confirmed the clinical, humanistic, and economical superiority of the collaborative interventions to improve asthma outcomes as compared to usual care. This review distinguished many studies reporting the collaborative interventions. Involving CPs in clinical decision-making in collaboration with GPs is an emerging trend worldwide, and a significant number of

studies were conducted on collaborative practice between CP and GP in recent years in European countries.^{5,43,47,48}

The results were consistently significant for improvements in inhalation technique, which is a core element of better asthma control. Similarly, the need of rescue medicine decreased (high usage of rescue medication means poor

Figure 6 Narrative synthesis of the included studies.

Abbreviations: ED, emergency department; FEV, forced expiratory volume; FVC, forced vital capacity; LABA, long acting beta-agonist; PEFR, pulmonary expiratory flow rate; QoL, quality-of-life; SABA, short acting beta-agonist.

asthma control) which contextually proved the better management of asthma in the intervention group.

Achieving and sustaining asthma control and improvement in QoL are the foundation of asthma management. These interventions on the whole have significantly improved not only the medication use and management, but also substantially contributed towards better control and self-management, as well as enhanced knowledge and QoL. The possible reasons for this improvement could be attributed to:

- (a) Patient's enhanced knowledge of diseases and medication which may halt the patient's false belief on pseudo medicine or therapies.
- (b) Patient's better understanding of the identification of triggers and ways to minimize or handle effectively.
- (c) Written self-management strategies.
- (d) Corrected inhalation technique.
- (e) Better understanding and adherence to medication regimen (the appropriate use of reliever and preventive medication).
- (f) Refined collaboration of caregivers, where they update and refer patients to each other for medications review, advice, education, and counseling, projecting a sense of ownership of patients.

The current review presents a different but important consideration; compared with other systematic reviews which cover individual CPs interventions, the focus was on collaborative practice between CP and GP. An interesting observation made in this review was the presence of a general correlation between the impact of intervention on patients' multiple outcomes and score on collaboration

scale; that is, the higher the collaboration-score, the higher would be the positive patients' outcomes. For instance, all studies with collaboration-scores 10/10 (indicator of highest form collaboration) has significantly improved all outcomes (clinical, humanistic, and economical) in the intervention group.^{15,43,45,47,49,50} On the contrary, the studies with a Collaboration scale score ≤ 5 have shown multiple outcomes with no significant statistical difference in the intervention group as compared to the control group.^{42,51–53}

In his doctoral thesis, Amirthalingam⁵⁴ pointed out that collaboration between CP-GP rather than solo CPs' interventions could produce more promising results in clinical and humanistic outcomes in chronic diseases like hypertension. Our review seconded the findings for asthma and established the fact that collaborative intervention in asthma management is promising, especially for clinical and humanistic outcomes. The positive impact of collaborative practice on asthma management has implications for practice and policy. The policy-makers should consider the untapped potential and formulate policies which favor the role of CPs in medication management, especially in chronic diseases. Positive experiences from this collaborative model approach of chronic diseases management should be taken as a lesson for countries where the concept of single care provider is still widely operated.

A notable point which may constitute high heterogeneity in the results was the use of diverse data collection tools (questionnaires) in the added studies for the same outcome. For instance, QoL, asthma knowledge, and adherence to medications were assessed in various studies using three, four, and two different types of questionnaire, respectively. This made the situation overly complicated,

Table 3 Overall meta-analysis

Outcome (Number of studies)	Procedure for overall meta-analysis	(Participants) {I ² } [Effect size (95% CI)] <Interpretation of effect size>	Subgroup performed (yes/no)	Forest Plot of overall meta-analysis																																																																		
Asthma severity (n=5)	<ul style="list-style-type: none">MA was possible on 3/5 studies but carried out on 2/5.$\bar{x}$ and SD were given in (n=1).⁵²Data of (n=2) were convertible to $\bar{x}$ and SD by the formulas.^{46,56}Data of (n=2) were not convertible to $\bar{x}$ and SD, hence, could not be pooled.^{45,49}Overall MA resulted (I²=79%), the reason of heterogeneity was a single outlier⁴⁶ which when removed from MA reduced the heterogeneity to (I²=0%). Thus, subgroup analysis was not required.	(420) {0%} [-0.4 (-0.58, -0.19)] <Small>	No	<table><thead><tr><th>Study or Subgroup</th><th>CP-AP Intervention</th><th>Usual care/No care</th><th>Weight</th><th>Std. Mean Difference</th><th>Std. Mean Difference</th></tr><tr><th></th><th>Mean</th><th>SD</th><th>Total</th><th>IV, Random, 95% CI</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Mangione et al., 2005</td><td>1.7</td><td>0.8</td><td>128</td><td>62.5%</td><td>-0.35 [-0.60, -0.10]</td></tr><tr><td>Schultz et al., 2001</td><td>1.26</td><td>0.71</td><td>101</td><td>37.5%</td><td>-0.45 [-0.77, -0.13]</td></tr><tr><td>Total (95% CI)</td><td></td><td></td><td>229</td><td>100.0%</td><td>-0.39 [-0.58, -0.19]</td></tr></tbody></table> <p>Heterogeneity: $\tau^2=0.00$; $\chi^2=0.23$, $df=1$ ($P=0.63$); $I^2=0\%$ Test for overall effect: $Z=3.80$ ($P<0.0001$) Favours CP-AP Favours Usual Care/No Care</p>	Study or Subgroup	CP-AP Intervention	Usual care/No care	Weight	Std. Mean Difference	Std. Mean Difference		Mean	SD	Total	IV, Random, 95% CI	IV, Random, 95% CI	Mangione et al., 2005	1.7	0.8	128	62.5%	-0.35 [-0.60, -0.10]	Schultz et al., 2001	1.26	0.71	101	37.5%	-0.45 [-0.77, -0.13]	Total (95% CI)			229	100.0%	-0.39 [-0.58, -0.19]																																				
Study or Subgroup	CP-AP Intervention	Usual care/No care	Weight	Std. Mean Difference	Std. Mean Difference																																																																	
	Mean	SD	Total	IV, Random, 95% CI	IV, Random, 95% CI																																																																	
Mangione et al., 2005	1.7	0.8	128	62.5%	-0.35 [-0.60, -0.10]																																																																	
Schultz et al., 2001	1.26	0.71	101	37.5%	-0.45 [-0.77, -0.13]																																																																	
Total (95% CI)			229	100.0%	-0.39 [-0.58, -0.19]																																																																	
Asthma control (n=10)	<ul style="list-style-type: none">MA was possible on 8/10 studies and carried out on 7/10.$\bar{x}$ and SD were given in (n=5).^{15,46,47,51,55,63}Data of (n=3) were convertible to $\bar{x}$ and SD by the formulas.^{42,43,49}Data of (n=1) were not convertible to $\bar{x}$ and SD, hence, could not be pooled.⁵Data were not provided in (n=1).⁵³Overall MA resulted (I²=81%), so subgroup analysis was required. However, Bereznicki et al^{55,63} could not be combined in any subgroup being the only CC.	(3090) {81%} [0.3 (0.13, 0.51)] <Small>	Yes	<table><thead><tr><th>Study or Subgroup</th><th>CP-AP Interventions</th><th>Usual care/No care</th><th>Weight</th><th>Std. Mean Difference</th><th>Std. Mean Difference</th></tr><tr><th></th><th>Mean</th><th>SD</th><th>Total</th><th>IV, Random, 95% CI</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>B.J. Bereznicki et al., 2008</td><td>18.5</td><td>4</td><td>706</td><td>16.3%</td><td>0.43 [0.31, 0.55]</td></tr><tr><td>Bandaru Siani et al., 2004</td><td>42.5</td><td>5.2</td><td>38</td><td>7.8%</td><td>0.79 [0.28, 1.29]</td></tr><tr><td>C. Amour et al., 2007</td><td>23.43</td><td>5.21</td><td>153</td><td>14.2%</td><td>-0.09 [-0.30, 0.13]</td></tr><tr><td>C.L. Amour et al., 2013</td><td>26.01</td><td>5.51</td><td>174</td><td>14.2%</td><td>0.61 [0.39, 0.82]</td></tr><tr><td>Chenais et al., 2006</td><td>1.88</td><td>0.81</td><td>28</td><td>2.7%</td><td>-0.49 [-0.91, 0.11]</td></tr><tr><td>Gunn et al., 2014</td><td>19.02</td><td>4.34</td><td>93</td><td>12.3%</td><td>0.51 [0.21, 0.80]</td></tr><tr><td>Martini et al., 2017</td><td>22</td><td>4.44</td><td>400</td><td>15.9%</td><td>0.41 [0.27, 0.55]</td></tr><tr><td>Melnyk et al., 2008</td><td>20.2</td><td>3.5</td><td>80</td><td>11.6%</td><td>0.13 [-0.20, 0.44]</td></tr><tr><td>Total (95% CI)</td><td></td><td></td><td>1674</td><td>100.0%</td><td>0.32 [0.13, 0.51]</td></tr></tbody></table> <p>Heterogeneity: $\tau^2=0.05$; $\chi^2=37.33$, $df=7$ ($P<0.00001$); $I^2=81\%$ Test for overall effect: $Z=3.28$ ($P=0.001$) Favours CP-AP Favours Usual Care/No Care</p>	Study or Subgroup	CP-AP Interventions	Usual care/No care	Weight	Std. Mean Difference	Std. Mean Difference		Mean	SD	Total	IV, Random, 95% CI	IV, Random, 95% CI	B.J. Bereznicki et al., 2008	18.5	4	706	16.3%	0.43 [0.31, 0.55]	Bandaru Siani et al., 2004	42.5	5.2	38	7.8%	0.79 [0.28, 1.29]	C. Amour et al., 2007	23.43	5.21	153	14.2%	-0.09 [-0.30, 0.13]	C.L. Amour et al., 2013	26.01	5.51	174	14.2%	0.61 [0.39, 0.82]	Chenais et al., 2006	1.88	0.81	28	2.7%	-0.49 [-0.91, 0.11]	Gunn et al., 2014	19.02	4.34	93	12.3%	0.51 [0.21, 0.80]	Martini et al., 2017	22	4.44	400	15.9%	0.41 [0.27, 0.55]	Melnyk et al., 2008	20.2	3.5	80	11.6%	0.13 [-0.20, 0.44]	Total (95% CI)			1674	100.0%	0.32 [0.13, 0.51]
Study or Subgroup	CP-AP Interventions	Usual care/No care	Weight	Std. Mean Difference	Std. Mean Difference																																																																	
	Mean	SD	Total	IV, Random, 95% CI	IV, Random, 95% CI																																																																	
B.J. Bereznicki et al., 2008	18.5	4	706	16.3%	0.43 [0.31, 0.55]																																																																	
Bandaru Siani et al., 2004	42.5	5.2	38	7.8%	0.79 [0.28, 1.29]																																																																	
C. Amour et al., 2007	23.43	5.21	153	14.2%	-0.09 [-0.30, 0.13]																																																																	
C.L. Amour et al., 2013	26.01	5.51	174	14.2%	0.61 [0.39, 0.82]																																																																	
Chenais et al., 2006	1.88	0.81	28	2.7%	-0.49 [-0.91, 0.11]																																																																	
Gunn et al., 2014	19.02	4.34	93	12.3%	0.51 [0.21, 0.80]																																																																	
Martini et al., 2017	22	4.44	400	15.9%	0.41 [0.27, 0.55]																																																																	
Melnyk et al., 2008	20.2	3.5	80	11.6%	0.13 [-0.20, 0.44]																																																																	
Total (95% CI)			1674	100.0%	0.32 [0.13, 0.51]																																																																	

(Continued)

Table 3 (Continued).

Outcome (Number of studies)	Procedure for overall meta-analysis	(Participants) {I ² } [Effect size (95% CI)] <Interpretation of effect size>	Subgroup performed (yes/no)	Forest Plot of overall meta-analysis																																																						
Asthma symp- toms (n=10)	<ul style="list-style-type: none">MA was possible on 5/10 studies and carried out on 5/10.$\bar{x}$ and SD were given in (n=4).^{51,52,57,59}Data of (n=1) were convertible to $\bar{x}$ and SD by the formulas.⁶²Data of (n=3) were not convertible to $\bar{x}$ and SD, hence, could not be pooled.^{45,50,53}Data were not provided in (n=2).^{55,61,63}Overall MA resulted (I²=64%), the reason of heterogeneity was a single outlier⁵⁷ which when removed from MA reduced the heterogeneity to (I²=0%). Thus, subgroup analysis was not required.	(871) {0%} [-0.4 (-0.50, -0.23)] <Small>	No	<table><thead><tr><th>Study or Subgroup</th><th>CP-CP Intervention</th><th>Usual Care/No Care</th><th>Mean</th><th>SD</th><th>Total</th><th>Weight</th><th>Std. Mean Difference</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Heitkamp et al., 2001</td><td>1.55</td><td>0.68</td><td>208</td><td>1.88</td><td>0.65</td><td>201</td><td>46.8%</td><td>-0.43 [-0.62, -0.23]</td></tr><tr><td>Marijagane et al., 2005</td><td>2.5</td><td>2.3</td><td>128</td><td>3.1</td><td>2.3</td><td>128</td><td>29.7%</td><td>-0.26 [-0.51, -0.01]</td></tr><tr><td>Melnyk et al., 2008</td><td>3.9</td><td>9.1</td><td>80</td><td>10.7</td><td>19.3</td><td>70</td><td>17.0%</td><td>-0.49 [-0.78, -0.19]</td></tr><tr><td>Nardi et al., 2000</td><td>1.8</td><td>3</td><td>28</td><td>2.4</td><td>3.1</td><td>28</td><td>6.5%</td><td>-0.19 [-0.72, 0.33]</td></tr><tr><td>Total (95% CI)</td><td></td><td></td><td>444</td><td></td><td></td><td>427</td><td>100.0%</td><td>-0.37 [-0.50, -0.23]</td></tr></tbody></table> <p>Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 1.63$, $df = 3$ ($P = 0.65$), $I^2 = 0\%$ Test for overall effect: $Z = 5.38$ ($P < 0.00001$)</p>	Study or Subgroup	CP-CP Intervention	Usual Care/No Care	Mean	SD	Total	Weight	Std. Mean Difference	IV, Random, 95% CI	Heitkamp et al., 2001	1.55	0.68	208	1.88	0.65	201	46.8%	-0.43 [-0.62, -0.23]	Marijagane et al., 2005	2.5	2.3	128	3.1	2.3	128	29.7%	-0.26 [-0.51, -0.01]	Melnyk et al., 2008	3.9	9.1	80	10.7	19.3	70	17.0%	-0.49 [-0.78, -0.19]	Nardi et al., 2000	1.8	3	28	2.4	3.1	28	6.5%	-0.19 [-0.72, 0.33]	Total (95% CI)			444			427	100.0%	-0.37 [-0.50, -0.23]
Study or Subgroup	CP-CP Intervention	Usual Care/No Care	Mean	SD	Total	Weight	Std. Mean Difference	IV, Random, 95% CI																																																		
Heitkamp et al., 2001	1.55	0.68	208	1.88	0.65	201	46.8%	-0.43 [-0.62, -0.23]																																																		
Marijagane et al., 2005	2.5	2.3	128	3.1	2.3	128	29.7%	-0.26 [-0.51, -0.01]																																																		
Melnyk et al., 2008	3.9	9.1	80	10.7	19.3	70	17.0%	-0.49 [-0.78, -0.19]																																																		
Nardi et al., 2000	1.8	3	28	2.4	3.1	28	6.5%	-0.19 [-0.72, 0.33]																																																		
Total (95% CI)			444			427	100.0%	-0.37 [-0.50, -0.23]																																																		
FEV ₁ (n=5)	<ul style="list-style-type: none">MA was possible on 3/5 studies but carried out on 2/5.$\bar{x}$ and SD were given in (n=1).⁵²Data of (n=2) were convertible to $\bar{x}$ and SD by the formulas.^{49,56}Data of (n=2) were not convertible to $\bar{x}$ and SD, hence could not be pooled.^{42,45}Overall MA resulted (I²=55%), the reason of heterogeneity was a single outlier,⁴⁹ which when removed from MA reduced the heterogeneity to (I²=0%). Thus, sub-group analysis was not required.	(420) {0%} [0.1 (-0.13, 0.25)] <Non-Significant>	No	<table><thead><tr><th>Study or Subgroup</th><th>CP-CP Intervention</th><th>Usual Care/No Care</th><th>Mean</th><th>SD</th><th>Total</th><th>Weight</th><th>Std. Mean Difference</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Marijagane et al., 2005</td><td>2.9</td><td>1</td><td>128</td><td>2.8</td><td>1</td><td>128</td><td>62.2%</td><td>0.10 [-0.15, 0.34]</td></tr><tr><td>Schultz et al., 2001</td><td>6.4</td><td>42.78</td><td>101</td><td>6.7</td><td>38.986</td><td>63</td><td>37.8%</td><td>-0.01 [-0.32, 0.31]</td></tr><tr><td>Total (95% CI)</td><td></td><td></td><td>229</td><td></td><td></td><td>191</td><td>100.0%</td><td>0.06 [-0.13, 0.25]</td></tr></tbody></table> <p>Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 1.18$, $df = 1$ ($P = 0.28$), $I^2 = 0\%$ Test for overall effect: $Z = 0.80$ ($P = 0.55$)</p>	Study or Subgroup	CP-CP Intervention	Usual Care/No Care	Mean	SD	Total	Weight	Std. Mean Difference	IV, Random, 95% CI	Marijagane et al., 2005	2.9	1	128	2.8	1	128	62.2%	0.10 [-0.15, 0.34]	Schultz et al., 2001	6.4	42.78	101	6.7	38.986	63	37.8%	-0.01 [-0.32, 0.31]	Total (95% CI)			229			191	100.0%	0.06 [-0.13, 0.25]																		
Study or Subgroup	CP-CP Intervention	Usual Care/No Care	Mean	SD	Total	Weight	Std. Mean Difference	IV, Random, 95% CI																																																		
Marijagane et al., 2005	2.9	1	128	2.8	1	128	62.2%	0.10 [-0.15, 0.34]																																																		
Schultz et al., 2001	6.4	42.78	101	6.7	38.986	63	37.8%	-0.01 [-0.32, 0.31]																																																		
Total (95% CI)			229			191	100.0%	0.06 [-0.13, 0.25]																																																		

(Continued)

Table 3 (Continued).

Outcome (Number of studies)	Procedure for overall meta-analysis	(Participants) {I ² } [Effect size (95% CI)] <Interpretation of effect size>	Subgroup performed (yes/no)	Forest Plot of overall meta-analysis																																																													
PEFR (n=8)	<ul style="list-style-type: none">MA was possible on 4/8 studies and carried out on 4/8.$\bar{x}$ and SD were given in (n=2).^{51,52} However,⁵¹ could not be combined being the only RCT.Data of (n=2) were convertible to $\bar{x}$ and SD by the formulas.^{56,62}Data of (n=2) were not convertible to $\bar{x}$ and SD, hence, could not be pooled.^{46,53}Data were not provided in (n=2).^{50,61}Overall MA resulted (I²=22%), so subgroup analysis was not required.	(983) {22%} [0.2 (0.05, 0.34)] <Small>	No	<table><thead><tr><th>Study or Subgroup</th><th>CP-CP Intervention</th><th>Usual care/No care</th><th>Total</th><th>Weight</th><th>IV, Random, 95% CI</th><th>Sum, Mean Difference</th></tr><tr><th></th><th>Mean</th><th>SD</th><th>Total</th><th>Mean</th><th>SD</th><th>Total</th><th>Weight</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Helong et al., 2001</td><td>478.25</td><td>114.5</td><td>209</td><td>445.73</td><td>124.26</td><td>204</td><td>37.8%</td><td>0.26 [0.06, 0.45]</td></tr><tr><td>Mangagane et al., 2005</td><td>433.4</td><td>110.3</td><td>128</td><td>402.9</td><td>114.9</td><td>128</td><td>26.8%</td><td>0.27 [0.02, 0.52]</td></tr><tr><td>Melnyk et al., 2008</td><td>84</td><td>19.4</td><td>80</td><td>79.1</td><td>19</td><td>70</td><td>17.4%</td><td>0.25 [-0.07, 0.58]</td></tr><tr><td>Schulz et al., 2001</td><td>377</td><td>121.51</td><td>101</td><td>388</td><td>148</td><td>83</td><td>18.0%</td><td>-0.08 [-0.40, 0.23]</td></tr><tr><td>Total (95% CI)</td><td></td><td></td><td>516</td><td></td><td></td><td></td><td>100.0%</td><td>0.20 [0.05, 0.34]</td></tr></tbody></table> <p>Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 3.92$, $df = 3$ ($P = 0.28$); $I^2 = 22\%$ Test for overall effect: $Z = 2.88$ ($P = 0.008$)</p> <p>Favours [CP-CP] Favours [CP-GP]</p>	Study or Subgroup	CP-CP Intervention	Usual care/No care	Total	Weight	IV, Random, 95% CI	Sum, Mean Difference		Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Helong et al., 2001	478.25	114.5	209	445.73	124.26	204	37.8%	0.26 [0.06, 0.45]	Mangagane et al., 2005	433.4	110.3	128	402.9	114.9	128	26.8%	0.27 [0.02, 0.52]	Melnyk et al., 2008	84	19.4	80	79.1	19	70	17.4%	0.25 [-0.07, 0.58]	Schulz et al., 2001	377	121.51	101	388	148	83	18.0%	-0.08 [-0.40, 0.23]	Total (95% CI)			516				100.0%	0.20 [0.05, 0.34]
Study or Subgroup	CP-CP Intervention	Usual care/No care	Total	Weight	IV, Random, 95% CI	Sum, Mean Difference																																																											
	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI																																																									
Helong et al., 2001	478.25	114.5	209	445.73	124.26	204	37.8%	0.26 [0.06, 0.45]																																																									
Mangagane et al., 2005	433.4	110.3	128	402.9	114.9	128	26.8%	0.27 [0.02, 0.52]																																																									
Melnyk et al., 2008	84	19.4	80	79.1	19	70	17.4%	0.25 [-0.07, 0.58]																																																									
Schulz et al., 2001	377	121.51	101	388	148	83	18.0%	-0.08 [-0.40, 0.23]																																																									
Total (95% CI)			516				100.0%	0.20 [0.05, 0.34]																																																									
Inhalation technique (n= 11)	<ul style="list-style-type: none">MA was possible on 4/11 studies but carried out on 2/11.$\bar{x}$ and SD were given in (n=2).^{51,52}Data of (n=2) were convertible to $\bar{x}$ and SD by the formulas.^{56,62}Data of (n=4) were not convertible to $\bar{x}$ and SD, hence could not be pooled.^{5,42,47,50}Data were not provided in (n=3).^{46,49,61}Overall MA resulted (I²=98%), so subgroup analysis was required. However,⁵¹ could not be combined in any subgroup being the only RCT.Subgroup (PP-CI) MA resulted (I²=98%), the reason of heterogeneity was single outlier,⁶² which when removed from MA reduced the heterogeneity to (I²=0%).	(967) {98%} [0.5 (-0.39, 1.44)] <Medium>	Yes	<table><thead><tr><th>Study or Subgroup</th><th>CP-CP Intervention</th><th>Usual care/No care</th><th>Total</th><th>Weight</th><th>IV, Random, 95% CI</th><th>Sum, Mean Difference</th></tr><tr><th></th><th>Mean</th><th>SD</th><th>Total</th><th>Mean</th><th>SD</th><th>Total</th><th>Weight</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Helong et al., 2001</td><td>0.17</td><td>0.65</td><td>207</td><td>0.75</td><td>1.21</td><td>190</td><td>25.3%</td><td>-0.60 [-0.90, -0.40]</td></tr><tr><td>Mangagane et al., 2005</td><td>6.6</td><td>1</td><td>128</td><td>5.2</td><td>1.5</td><td>128</td><td>25.1%</td><td>1.10 [0.83, 1.36]</td></tr><tr><td>Melnyk et al., 2008</td><td>93.2</td><td>10.7</td><td>80</td><td>83.7</td><td>22.5</td><td>70</td><td>24.8%</td><td>0.55 [0.22, 0.88]</td></tr><tr><td>Schulz et al., 2001</td><td>8.7</td><td>0.51</td><td>101</td><td>5.8</td><td>1.2</td><td>83</td><td>24.8%</td><td>1.06 [0.73, 1.40]</td></tr><tr><td>Total (95% CI)</td><td></td><td></td><td>516</td><td></td><td></td><td></td><td>100.0%</td><td>0.52 [-0.39, 1.44]</td></tr></tbody></table> <p>Heterogeneity: $\tau^2 = 0.85$; $\chi^2 = 134.23$, $df = 3$ ($P < 0.00001$); $I^2 = 98\%$ Test for overall effect: $Z = 1.12$ ($P = 0.26$)</p> <p>Favours [CP-CP] Favours [CP-GP]</p>	Study or Subgroup	CP-CP Intervention	Usual care/No care	Total	Weight	IV, Random, 95% CI	Sum, Mean Difference		Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Helong et al., 2001	0.17	0.65	207	0.75	1.21	190	25.3%	-0.60 [-0.90, -0.40]	Mangagane et al., 2005	6.6	1	128	5.2	1.5	128	25.1%	1.10 [0.83, 1.36]	Melnyk et al., 2008	93.2	10.7	80	83.7	22.5	70	24.8%	0.55 [0.22, 0.88]	Schulz et al., 2001	8.7	0.51	101	5.8	1.2	83	24.8%	1.06 [0.73, 1.40]	Total (95% CI)			516				100.0%	0.52 [-0.39, 1.44]
Study or Subgroup	CP-CP Intervention	Usual care/No care	Total	Weight	IV, Random, 95% CI	Sum, Mean Difference																																																											
	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI																																																									
Helong et al., 2001	0.17	0.65	207	0.75	1.21	190	25.3%	-0.60 [-0.90, -0.40]																																																									
Mangagane et al., 2005	6.6	1	128	5.2	1.5	128	25.1%	1.10 [0.83, 1.36]																																																									
Melnyk et al., 2008	93.2	10.7	80	83.7	22.5	70	24.8%	0.55 [0.22, 0.88]																																																									
Schulz et al., 2001	8.7	0.51	101	5.8	1.2	83	24.8%	1.06 [0.73, 1.40]																																																									
Total (95% CI)			516				100.0%	0.52 [-0.39, 1.44]																																																									

(Continued)

Table 3 (Continued).

Outcome (Number of studies)	Procedure for overall meta-analysis	(Participants) {I ² } [Effect size (95% CI)] <Interpretation of effect size>	Subgroup performed (yes/no)	Forest Plot of overall meta-analysis			
SABA usage (n=9)	<ul style="list-style-type: none"> MA was possible on 5/9 studies but carried out on 5/9. $\bar{x}$ and SD were given in (n=1).⁵¹ Data of (n=4) were convertible to $\bar{x}$ and SD by the formulas.^{55,58,62-64} Data of (n=3) were not convertible to $\bar{x}$ and SD, hence could not be pooled.^{15,47,53} Data were not provided in (n=1).⁴⁶ Overall MA resulted ($I^2=88\%$), so subgroup analysis was required. However,⁶² could not be combined in any subgroup being the only CI. 	(3347) {88%} [-0.2 (-0.39, 0.06)] <Small>	Yes				
Corticosteroid usage (n=9)	<ul style="list-style-type: none"> MA was possible on 4/9 studies and carried out on 4/9. Data of (n=4) were convertible to $\bar{x}$ and SD by the formulas.^{48,55,58,62-64} However,⁶² could not be combined being the only CI. Data of (n=5) were not convertible to $\bar{x}$ and SD, hence could not be pooled.^{15,42,46,47,53} Overall MA resulted ($I^2=0\%$), so subgroup analysis was not required. 	(2588) {0%} [-0.0 (-0.08, 0.07)] <Non-Significant>	No				
Preventor-to-reliever ratio (n=4)	<ul style="list-style-type: none"> MA was possible on 3/4 studies and carried out on 3/4. Data of (n=3) were convertible to $\bar{x}$ and SD by the formulas.^{48,55,58,63,64} Data were not provided in (n=1).⁴⁶ Overall MA resulted ($I^2=0\%$), so subgroup analysis was not required. 	(2284) {0%} [0.1 (0.05, 0.21)] <Non-Significant>	No				

(Continued)

Table 3 (Continued).

Outcome (Number of studies)	Procedure for overall meta-analysis	(Participants) {I ² } [Effect size (95% CI)] <Interpretation of effect size>	Subgroup performed (yes/no)	Forest Plot of overall meta-analysis
Hospital visit (n=8)	<ul style="list-style-type: none"> MA was possible on 4/8 studies and carried out on 4/8. Number of patients and events were given in (n=4).^{15,45,51,62} Data of (n=3) were not convertible to number of events, hence, could not be pooled.^{42,50,53} Data were not provided in (n=1).⁶¹ Overall MA resulted (I²=0%), so subgroup analysis was not required. 	(949) {0%} [0.3 (0.15, 0.77)] <Small>	No	<p>Forest Plot of overall meta-analysis for Hospital visit (n=8). The plot shows Odds Ratio (OR) for CP-CP vs Usual care/No care. The pooled OR is 0.34 [0.15, 0.77]. Heterogeneity: Tau² = 0.00; Chi² = 7.50, df = 3 (P = 0.48); I² = 0%. Test for overall effect: Z = 2.60 (P = 0.009).</p>
ED visit (n=6)	<ul style="list-style-type: none"> MA was possible on 4/6 studies and carried out on 4/6. Number of patients and events were given in (n=4).^{15,45,51,62} Data of (n=2) were not convertible to number of events, hence could not be pooled.^{42,50,53} Overall MA resulted (I²=19%), so subgroup analysis was not required. 	(949) {19%} [0.5 (0.24, 1.01)] <Medium>	No	<p>Forest Plot of overall meta-analysis for ED visit (n=6). The plot shows Odds Ratio (OR) for CP-CP vs Usual care/No care. The pooled OR is 0.49 [0.24, 1.01]. Heterogeneity: Tau² = 0.13; Chi² = 3.70, df = 3 (P = 0.30); I² = 19%. Test for overall effect: Z = 1.83 (P = 0.05).</p>
Adherence (n=8)	<ul style="list-style-type: none"> MA was possible on 5/8 studies and carried out on 5/8. $\bar{x}$ and SD were given in (n=4).^{47,48,52,53} Data of (n=1) were convertible to $\bar{x}$ and SD by the formulas.⁴⁹ Data of (n=3) were not convertible to $\bar{x}$ and SD, hence, could not be pooled.^{5,15,43} Overall MA resulted (I²=73%), so sub-group analysis was required. 	(1124) {73%} [0.3 (0.08, 0.56)] <Small>	Yes	<p>Forest Plot of overall meta-analysis for Adherence (n=8). The plot shows Std. Mean Difference (SMD) for CP-CP vs Usual care/No care. The pooled SMD is 0.32 [0.08, 0.56]. Heterogeneity: Tau² = 0.05; Chi² = 14.94, df = 4 (P = 0.005); I² = 73%. Test for overall effect: Z = 2.93 (P = 0.003).</p>

(Continued)

Table 3 (Continued).

Outcome (Number of studies)	Procedure for overall meta-analysis	(Participants) {I ² } [Effect size (95% CI)] <Interpretation of effect size>	Subgroup performed (yes/no)	Forest Plot of overall meta-analysis
Asthma knowledge (n=11)	<ul style="list-style-type: none"> MA was possible on 10/11 studies and carried out on 10/11. $\bar{x}$ and SD were given in (n=7).^{44,46,47,51,52,55,60,63} Data of (n=3) were convertible to $\bar{x}$ and SD by the formulas.^{49,56,62} Data of (n=1) were not convertible to $\bar{x}$ and SD, hence could not be pooled.⁵³ Overall MA resulted (I²=84%), so sub-group analysis was required. However, Bereznicki et al^{55,63} could not be combined in any subgroup being the only CC. 	(3110) {84%} [0.6 (0.36, 0.76)] <Medium>	Yes	<p> Std. Mean Difference IV, Random, 95% CI Total (95% CI) Heterogeneity: Tau²=0.07; Chi²=49.82, df=8 (P<0.00001), I²=84% Test for overall effect: Z=5.38 (P<0.00001) </p>

(Continued)

Table 3 (Continued).

Outcome (Number of studies)	Procedure for overall meta-analysis	(Participants) { I^2 [Effect size (95% CI)] <Interpretation of effect size>	Subgroup performed (yes/no)	Forest Plot of overall meta-analysis
Quality-of-life (n=15)	<ul style="list-style-type: none"> MA was possible on 10/15 studies and carried out on 10/15. $\bar{x}$ and SD were given in (n=7).^{15,44,46,47,51,52,55,63} Data of (n=3) were convertible to $\bar{x}$ and SD by the formulas.^{49,56,62} Data of (n=4) were not convertible to $\bar{x}$ and SD, hence could not be pooled.^{43,45,50,53} Data were not provided in (n=1).⁶¹ There were two different scales used to measure QoL. One scale lower values indicate improvement in QoL (AQLQ), on the other hand, higher values represent improvement in QoL (LWAAQ). Thus, overall MA was performed for both categories (ie, studies which used same tools were pooled up). In AQLQ category ($I^2=95\%$), so subgroup analysis was required. In LWAAQ category ($I^2=92\%$), however, the reason of heterogeneity was single outlier,⁶² which when removed from MA reduced the heterogeneity to ($I^2=0\%$), thus, so subgroup analysis was not required. 	(2208) {95%} [-0.2 (-0.64, 0.20)] <Small>	Yes	<p>AQLO</p> <p>LWAAQ</p>

Notes: Data refer to values of any outcome at end point; meta-analysis was performed on the end point data ($\bar{x}$ and standard deviation values) of each outcome; mean=mean change+mean at baseline; SD= $\sqrt{Nx}$ (upper limit-lower limit)/t-distribution (SD at endpoint was calculated by converting 95% CI); SD=SE $\sqrt{N}$; N =number of studies; $\bar{x}$ =mean; SD=standard deviation; MA, meta-analysis; CC, case-control; RCT, randomized controlled trials; Cont, controlled intervention; PEFR, peak expiratory flow rate; FEV₁, forced expiratory volume in 1 second; AQLO, Asthma Quality-of-Life Questionnaire; LWAAQ, Living with Asthma Questionnaire; NC, no care; CP, community pharmacist; GP, general practitioner; RCT, randomized controlled trials; C-RCT, clustered randomized controlled trial; PP, pre-post.

Table 4 Sub-group meta-analysis results

Outcome (number of studies)	Procedure for subgroup meta-analysis	(Number of participants) {I ² } [Effect size (95% CI)] <Interpretation of effect size>			Forest Plot of subgroup meta-analysis
		RCT-CRCT	PP-CI/CC	Total	
Asthma control (n=10)	<ul style="list-style-type: none"> For subgroup analysis, the studies with similar research designs were pooled, based on which two subgroups were made RCT-CRCT and PP-CI. Subgroup analysis for RCT-CRCT, n=5 studies were combined,^{42,43,47,49,51} which resulted in (I²=83%). For PP-CI, n=2 studies were combined^{15,46} which resulted in (I²=0%). The total subgroup analysis resulted in (I²=77%). 	(1,704) {83%} [0.3 (0.03, 0.55)] <Small>	(253) {0%} [0.5 (0.28, 0.78)] <Medium>	(1,957) {77%} [0.4 (0.14, 0.56)] <Small>	<p>Forest plot for Asthma control. The plot shows individual study effect sizes (Mean, SD, Total, Mean, SD, Total) and pooled estimates (Std. Mean Difference, IV, Random, 95% CI) for RCT-CRCT and PP-CI subgroups. The total pooled effect size is 0.4 (95% CI 0.14 to 0.56) with I2=77%.</p>
Inhalation technique (n=11)	<ul style="list-style-type: none"> Mehuys et al⁵¹ could not be combined in any subgroup being the only RCT. So, no RCT-CRCT subgroup was made. Subgroup (PP-CI) MA, n=3 studies were pooled,^{52,56,62} which resulted (I²=98%), the reason of heterogeneity was single outlier,⁶² which when removed from MA reduced the heterogeneity to (I²=0%). 	—	(420) {0%} [1.1 (0.88, 1.29)] <Large>	—	<p>Forest plot for Inhalation technique. The plot shows individual study effect sizes (Mean, SD, Total, Mean, SD, Total) and pooled estimates (Std. Mean Difference, IV, Random, 95% CI) for the PP-CI subgroup. The total pooled effect size is 1.08 (95% CI 0.88 to 1.29) with I2=0%.</p>

(Continued)

Table 4 (Continued).

Outcome (number of studies)	Procedure for subgroup meta-analysis	(Number of participants) $\{I^2\}$ [Effect size (95% CI)] <Interpretation of effect size>			Forest Plot of subgroup meta-analysis																																																																																																																															
		RCT- CRCT	PP-CI/ CC	Total																																																																																																																																
SABA usage (n=9)	<ul style="list-style-type: none"> For subgroup analysis, the studies with similar research designs were pooled, based on which two subgroups were made RCT-CRCT and CC. Subgroup analysis for RCT-CRCT, n=2 studies were combined,^{51,58} which resulted in ($I^2=0\%$). For CC, n=2 studies were combined^{48,63,64} which resulted in ($I^2=96\%$). The total subgroup analysis resulted in ($I^2=89\%$). 	(998) {0%} [-0.2, (-0.28, -0.03)] <Small>	(2,269) {96%} [-0.2, (-0.72, 0.24)] <Small>	(3,267) {89%} [-0.2, (-0.43, 0.03)] <Small>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>CP-GP Intervention</th> <th>Usual care/No care</th> <th>Total</th> <th>Weight</th> <th>Std. Mean Difference</th> <th>IV, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>11.1.1 SABA (RCT)</td> <td>Mean</td> <td>SD</td> <td>Mean</td> <td>SD</td> <td></td> <td></td> </tr> <tr> <td>Bernardini et al., 2013</td> <td>553.43</td> <td>473.59</td> <td>444</td> <td>634.63</td> <td>454</td> <td>26.8%</td> </tr> <tr> <td>Bernardini et al., 2018</td> <td>616.7</td> <td>133</td> <td>80</td> <td>0.3</td> <td>1.26</td> <td>70.18%</td> </tr> <tr> <td>Subtotal (95% CI)</td> <td></td> <td></td> <td>484</td> <td></td> <td>504</td> <td>45.5%</td> </tr> <tr> <td>Heterogeneity: Tau²=0.00; Chi²=0.01, df=1 (P=0.91); I²=0%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Test for overall effect: Z=2.41 (P=0.02)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>11.1.2 SABA (CC)</td> <td>Mean</td> <td>SD</td> <td>Mean</td> <td>SD</td> <td></td> <td></td> </tr> <tr> <td>B. Berezowski et al., 2011</td> <td>217</td> <td>425.19</td> <td>421</td> <td>437</td> <td>485.19</td> <td>297.26.3%</td> </tr> <tr> <td>Bonnie J. Berezowski et al., 2010 (b)</td> <td>418.8</td> <td>1,263.7</td> <td>702</td> <td>414.5</td> <td>1,126.37</td> <td>849.28.0%</td> </tr> <tr> <td>Subtotal (95% CI)</td> <td></td> <td></td> <td>1123</td> <td></td> <td>1146</td> <td>54.2%</td> </tr> <tr> <td>Heterogeneity: Tau²=0.13; Chi²=20.33, df=1 (P<0.0001); I²=89%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Test for overall effect: Z=3.97 (P=0.33)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td></td> <td>1617</td> <td></td> <td>1650</td> <td>100.0%</td> </tr> <tr> <td>Heterogeneity: Tau²=0.05; Chi²=28.34, df=3 (P<0.0001); I²=89%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Test for overall effect: Z=3.97 (P=0.33)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Test for subgroup differences: Chi²=0.11, df=1 (P=0.74); I²=0%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		Study or Subgroup	CP-GP Intervention	Usual care/No care	Total	Weight	Std. Mean Difference	IV, Random, 95% CI	11.1.1 SABA (RCT)	Mean	SD	Mean	SD			Bernardini et al., 2013	553.43	473.59	444	634.63	454	26.8%	Bernardini et al., 2018	616.7	133	80	0.3	1.26	70.18%	Subtotal (95% CI)			484		504	45.5%	Heterogeneity: Tau ² =0.00; Chi ² =0.01, df=1 (P=0.91); I ² =0%							Test for overall effect: Z=2.41 (P=0.02)							11.1.2 SABA (CC)	Mean	SD	Mean	SD			B. Berezowski et al., 2011	217	425.19	421	437	485.19	297.26.3%	Bonnie J. Berezowski et al., 2010 (b)	418.8	1,263.7	702	414.5	1,126.37	849.28.0%	Subtotal (95% CI)			1123		1146	54.2%	Heterogeneity: Tau ² =0.13; Chi ² =20.33, df=1 (P<0.0001); I ² =89%							Test for overall effect: Z=3.97 (P=0.33)							Total (95% CI)			1617		1650	100.0%	Heterogeneity: Tau ² =0.05; Chi ² =28.34, df=3 (P<0.0001); I ² =89%							Test for overall effect: Z=3.97 (P=0.33)							Test for subgroup differences: Chi ² =0.11, df=1 (P=0.74); I ² =0%													
Study or Subgroup	CP-GP Intervention	Usual care/No care	Total	Weight	Std. Mean Difference	IV, Random, 95% CI																																																																																																																														
11.1.1 SABA (RCT)	Mean	SD	Mean	SD																																																																																																																																
Bernardini et al., 2013	553.43	473.59	444	634.63	454	26.8%																																																																																																																														
Bernardini et al., 2018	616.7	133	80	0.3	1.26	70.18%																																																																																																																														
Subtotal (95% CI)			484		504	45.5%																																																																																																																														
Heterogeneity: Tau ² =0.00; Chi ² =0.01, df=1 (P=0.91); I ² =0%																																																																																																																																				
Test for overall effect: Z=2.41 (P=0.02)																																																																																																																																				
11.1.2 SABA (CC)	Mean	SD	Mean	SD																																																																																																																																
B. Berezowski et al., 2011	217	425.19	421	437	485.19	297.26.3%																																																																																																																														
Bonnie J. Berezowski et al., 2010 (b)	418.8	1,263.7	702	414.5	1,126.37	849.28.0%																																																																																																																														
Subtotal (95% CI)			1123		1146	54.2%																																																																																																																														
Heterogeneity: Tau ² =0.13; Chi ² =20.33, df=1 (P<0.0001); I ² =89%																																																																																																																																				
Test for overall effect: Z=3.97 (P=0.33)																																																																																																																																				
Total (95% CI)			1617		1650	100.0%																																																																																																																														
Heterogeneity: Tau ² =0.05; Chi ² =28.34, df=3 (P<0.0001); I ² =89%																																																																																																																																				
Test for overall effect: Z=3.97 (P=0.33)																																																																																																																																				
Test for subgroup differences: Chi ² =0.11, df=1 (P=0.74); I ² =0%																																																																																																																																				
Adherence (n=8)	<ul style="list-style-type: none"> For subgroup analysis, the studies with similar research designs were pooled, based on which two subgroups were made RCT-CRCT and PP-CI. Subgroup analysis for RCT-CRCT, was performed on n=3 studies were combined,^{47,49,51} which resulted in ($I^2=75\%$). For PP-CI, n=2 studies were combined^{46,52} which resulted in ($I^2=81\%$). The total subgroup analysis resulted in ($I^2=73\%$). 	(801) {75%} [0.2, (-0.06, 0.51)] <Small>	(323) {81%} [0.5, (-0.11, 1.18)] <Medium>	(1,124) {73%} [0.3 (0.08, 0.56)] <Small>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>CP-GP Intervention</th> <th>Usual care/No care</th> <th>Total</th> <th>Weight</th> <th>Std. Mean Difference</th> <th>IV, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>11.1.1 Adherence (RCT, CRCT)</td> <td>Mean</td> <td>SD</td> <td>Mean</td> <td>SD</td> <td></td> <td></td> </tr> <tr> <td>C. Amour et al., 2007</td> <td>0.87</td> <td>4.047</td> <td>156</td> <td>0.97</td> <td>1.065</td> <td>173.23.3%</td> </tr> <tr> <td>C. L. Amour et al., 2013</td> <td>2.81</td> <td>1.9</td> <td>161</td> <td>2.25</td> <td>1.86</td> <td>161.23.2%</td> </tr> <tr> <td>Mehry et al., 2008</td> <td>90.3</td> <td>30.3</td> <td>80</td> <td>74.6</td> <td>36.5</td> <td>70.18.8%</td> </tr> <tr> <td>Subtotal (95% CI)</td> <td></td> <td></td> <td>397</td> <td></td> <td>404</td> <td>65.4%</td> </tr> <tr> <td>Heterogeneity: Tau²=0.05; Chi²=7.87, df=2 (P=0.02); I²=75%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Test for overall effect: Z=1.56 (P=0.12)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>11.1.2 Adherence (PP, CI)</td> <td>Mean</td> <td>SD</td> <td>Mean</td> <td>SD</td> <td></td> <td></td> </tr> <tr> <td>Baradaran Sani et al., 2004</td> <td>2.9</td> <td>1.4</td> <td>39</td> <td>1.75</td> <td>1</td> <td>28.12.5%</td> </tr> <tr> <td>Mangiacane et al., 2005</td> <td>7.1</td> <td>1.4</td> <td>128</td> <td>6.7</td> <td>1.8</td> <td>128.22.1%</td> </tr> <tr> <td>Subtotal (95% CI)</td> <td></td> <td></td> <td>167</td> <td></td> <td>156</td> <td>34.6%</td> </tr> <tr> <td>Heterogeneity: Tau²=0.18; Chi²=5.24, df=1 (P=0.02); I²=81%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Test for overall effect: Z=1.84 (P=0.10)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td></td> <td>564</td> <td></td> <td>560</td> <td>100.0%</td> </tr> <tr> <td>Heterogeneity: Tau²=0.05; Chi²=1.94, df=4 (P=0.095); I²=73%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Test for overall effect: Z=2.59 (P=0.010)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Test for subgroup differences: Chi²=0.75, df=1 (P=0.38); I²=0%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		Study or Subgroup	CP-GP Intervention	Usual care/No care	Total	Weight	Std. Mean Difference	IV, Random, 95% CI	11.1.1 Adherence (RCT, CRCT)	Mean	SD	Mean	SD			C. Amour et al., 2007	0.87	4.047	156	0.97	1.065	173.23.3%	C. L. Amour et al., 2013	2.81	1.9	161	2.25	1.86	161.23.2%	Mehry et al., 2008	90.3	30.3	80	74.6	36.5	70.18.8%	Subtotal (95% CI)			397		404	65.4%	Heterogeneity: Tau ² =0.05; Chi ² =7.87, df=2 (P=0.02); I ² =75%							Test for overall effect: Z=1.56 (P=0.12)							11.1.2 Adherence (PP, CI)	Mean	SD	Mean	SD			Baradaran Sani et al., 2004	2.9	1.4	39	1.75	1	28.12.5%	Mangiacane et al., 2005	7.1	1.4	128	6.7	1.8	128.22.1%	Subtotal (95% CI)			167		156	34.6%	Heterogeneity: Tau ² =0.18; Chi ² =5.24, df=1 (P=0.02); I ² =81%							Test for overall effect: Z=1.84 (P=0.10)							Total (95% CI)			564		560	100.0%	Heterogeneity: Tau ² =0.05; Chi ² =1.94, df=4 (P=0.095); I ² =73%							Test for overall effect: Z=2.59 (P=0.010)							Test for subgroup differences: Chi ² =0.75, df=1 (P=0.38); I ² =0%						
Study or Subgroup	CP-GP Intervention	Usual care/No care	Total	Weight	Std. Mean Difference	IV, Random, 95% CI																																																																																																																														
11.1.1 Adherence (RCT, CRCT)	Mean	SD	Mean	SD																																																																																																																																
C. Amour et al., 2007	0.87	4.047	156	0.97	1.065	173.23.3%																																																																																																																														
C. L. Amour et al., 2013	2.81	1.9	161	2.25	1.86	161.23.2%																																																																																																																														
Mehry et al., 2008	90.3	30.3	80	74.6	36.5	70.18.8%																																																																																																																														
Subtotal (95% CI)			397		404	65.4%																																																																																																																														
Heterogeneity: Tau ² =0.05; Chi ² =7.87, df=2 (P=0.02); I ² =75%																																																																																																																																				
Test for overall effect: Z=1.56 (P=0.12)																																																																																																																																				
11.1.2 Adherence (PP, CI)	Mean	SD	Mean	SD																																																																																																																																
Baradaran Sani et al., 2004	2.9	1.4	39	1.75	1	28.12.5%																																																																																																																														
Mangiacane et al., 2005	7.1	1.4	128	6.7	1.8	128.22.1%																																																																																																																														
Subtotal (95% CI)			167		156	34.6%																																																																																																																														
Heterogeneity: Tau ² =0.18; Chi ² =5.24, df=1 (P=0.02); I ² =81%																																																																																																																																				
Test for overall effect: Z=1.84 (P=0.10)																																																																																																																																				
Total (95% CI)			564		560	100.0%																																																																																																																														
Heterogeneity: Tau ² =0.05; Chi ² =1.94, df=4 (P=0.095); I ² =73%																																																																																																																																				
Test for overall effect: Z=2.59 (P=0.010)																																																																																																																																				
Test for subgroup differences: Chi ² =0.75, df=1 (P=0.38); I ² =0%																																																																																																																																				

(Continued)

Table 4 (Continued).

Outcome (number of studies)	Procedure for subgroup meta-analysis	(Number of participants) $\{I^2\}$ [Effect size (95% CI)] <Interpretation of effect size>	Forest Plot of subgroup meta-analysis			
			RCT-CRCT	PP-CI/CC	Total	
Asthma knowledge (n=11)	<ul style="list-style-type: none">For subgroup analysis, the studies with similar research designs were pooled, based on which two subgroups were made RCT-CRCT and PP-CI.Subgroup analysis for RCT-CRCT, n=3 studies were combined,^{48,50,52} which resulted in ($I^2=49\%$), the reason of heterogeneity was single outlier,² which when removed from MA reduced the heterogeneity to ($I^2=0\%$).For PP-CI, n=6 studies were combined^{44,46,52,56,60,62} which resulted in ($I^2=0\%$).The total subgroup analysis resulted in ($I^2=0\%$).		(702) {0%} [0.6 (0.40, 0.70)] <Medium>	(1,275) {0%} [0.7 (0.56, 0.79)] <Medium>	(1,977) {0%} [0.6 (0.54, 0.72)] <Medium>	
Quality-of-life (n=15)	<ul style="list-style-type: none">For subgroup analysis, the studies with similar research designs were pooled, based on which two subgroups were made RCT-CRCT and PP-CI.Subgroup analysis for RCT-CRCT, n=3 studies were combined,^{47,49,51} which resulted in ($I^2=90\%$).For PP-CI, n=2 studies were combined^{15,46} which resulted in ($I^2=82\%$).The total subgroup analysis resulted in ($I^2=87\%$).		(822) {90%} [-0.2, -0.61, 0.31] <Small>	(253) {82%} [-0.7, -1.41, 0.00] <Small>	(1,075) {87%} [-0.4, -0.71, 0.01] <Small>	

Notes: Data refer to values of any outcome at end point; meta-analysis was performed on the end point data ($\bar{x}$ and standard deviation values) of each outcome; mean=mean change+mean at baseline; SD= $\sqrt{N}(\text{upper limit}-\text{lower limit})/d$ -distribution (SD at endpoint was calculated by converting 95% CI); SD=SEM/ $\sqrt{N}$; SD=QR/1.35; SD=(maximum value in range-minimum value in range)/4.

Abbreviations: ¹ Heterogeneity; $\bar{x}$, mean; SD, standard deviation; MA, meta-analysis; C-RCT, clustered randomized controlled trial; PP, pre-post; CC, case-control; RCT, randomized controlled trials; CI, confidence interval; PEFR, peak expiratory flow rate; FEV₁, forced expiratory volume in 1 second; AQLQ, Asthma Quality-of-Life Questionnaire; LWAQ, Living with Asthma Questionnaire; n, number; UC, usual care; NC, no care; CP, community pharmacist; GP, general practitioner.

Table 5 Conclusion of outcomes based on the effect size

Outcome	Effect size of the outcome in overall meta-analysis	Effect size of the outcome in subgroup meta-analysis	
		RCT and CRCT	PP and CI/CC
Adherence	Small	Small	Medium
Asthma knowledge	Medium	Medium	Medium
Quality-of-life	Small (AQLQ, LWAQ)	Small (AQLQ)	Small (AQLQ)
FEV	Non-significant	NA	NA
PEFR	Small	NA	NA
Inhalation technique	Medium	NA	Large
Asthma severity	Small	NA	
Asthma control	Small	Small	Medium
Asthma symptoms	Small	NA	NA
SABA usage	Small	Small	Small
Corticosteroids usage	Non-significant	NA	NA
P/R ratio	Non-significant	NA	NA
Hospital visit	Small	NA	NA
ED visit	Medium	NA	NA
TOTAL	Small: n=8/14 (asthma severity, asthma control, asthma symptoms, PEFR, SABA usage, hospital visit, adherence, QoL (AQLQ, LWAQ))	Small: n=4/5 (asthma control, SABA usage, adherence, QoL (AQLQ))	Small: n=2/6 (SABA usage, QoL (AQLQ))
	Medium: n=3/14 (inhalation technique, ED visit, asthma knowledge)	Medium: n=1/5 (asthma knowledge)	Medium: n=3/6 (asthma control, adherence, asthma knowledge)
Large: n=0/14 Non-significant: n=3/14 (FEV, corticosteroids usage, preventer to reliever ratio)		Large: n=0/5 Non-significant: n=0/5	Large: n=1/6 (inhalation technique) Non-significant: n=0/6

Abbreviations: PEFR, peak expiratory flow rate; FEV₁, forced expiratory volume in 1 second; AQLQ, Asthma Quality-of-Life Questionnaire; LWAQ, Living with Asthma Questionnaire; n, number; NA, not applicable; PP, preventer to reliever; SABA, short-acting beta receptor agonist; ED, emergency department; PP, pre-post; CC, case-control; RCT, randomized controlled trials; CI, controlled intervention.

and it needs a standardized approach in future. We gave due importance to heterogeneity and executed subgroup analysis to find out the outliers and reasons of extreme heterogeneity.

In meta-analysis, out of the 11 outcomes which favored collaborative practice, eight outcomes resulted in small and three medium effect sizes. An important point regarding the magnitude of effect size obtained in the meta-analysis of various outcomes needs to be understood clearly. It is irrational to consider a large effect as the only important effect. It must be clear while drawing some conclusions that, for a policy-maker, a small effect size of 0.2 may also hold much attention. It is not just the numerical superiority of ES which matters, it is also the clinical relevance of the magnitude of an outcome, which holds much weight when making a policy change, ie, how big the problem is, and how much healthcare resource it utilizes. For a chronic disease with a huge burden, even a small ES may be of importance for the policy-makers.^{40,41}

A recent systematic review and meta-analysis was carried out to pool the data for adherence.²⁴ Authors reported significant improvements in adherence. However, the methodology used to conduct meta-analysis was different, and the scope of the review was not focused on collaborative interventions, yet the results hold a similar level of significance, as described in our results, and our data further confirm the strength of the evidence.

The expanded role of CPs in patient care and as a potential resource of relationship building between patient and primary caregiver was evident throughout the studies involved. The active participation of CPs and resultant positive outcomes could be attributed to various factors, which may include but are not limited to a) the advance certification programs on medicine management or pharmacotherapy or diseases management offered by the pharmacist associations in the countries reported (eg, the Australian Association of Consultant Pharmacy or American Pharmacist Association), b) the advance level trainings and modern curricula of pharmacy education with more emphasis on pharmacotherapy and patient care for a specific chronic disease management (asthma, diabetes, hypertension), and last but not least, c) the emerging scope of financial incentives (reimbursements) for the CPs.

Finally, there were a few economic studies with poor design. It was not possible to pool the studies because of limited data. There is a growing need for well-designed economic studies which appraise CP-GP collaborative

practice which may clear the blurred economic picture. This will further facilitate the decision-making in health-care systems.

The strength of the review is the systematic way evidence is collected, appraised, and depicted in the form of meta-analysis for 14 different kinds of outcomes, where many of the outcomes were not previously quantified. Furthermore, the meta-analysis procedure was discussed in detail, and subgroup analysis was carried out to get a clear picture of effect size.

Limitations

The following limitation of this review is noted: Every effort was made to make the search extensive, still, because of a lack of accessibility, we could not search International pharmaceutical abstracts and Embase. However, various other databases were added to compensate for this.

It was still difficult to group the outcomes in individual studies to pool the results in a meta-analysis. There were a number of factors which governed these limitations, for instance the medley of methodological designs, differences in patients' population, and prognostic variables, as well as a lack of definite statistical power to reach a conclusion. Besides, for continuous outcomes (ACT, ACQ scores, or asthma severity etc.), many studies have serious flaws which halt their addition into meta-analysis; for instance, missing standard deviation of mean change for control group,^{5,55} lack of control group measures,^{47,52} and lack of standard deviation of mean for both groups.^{46,56} We tried to convert the available data to the format which is suitable to add in the meta-analysis, but it was not plausible for all studies. However, for dichotomous outcome (eg, asthma control) a few studies were appropriate for meta-analysis.^{5,47,51} The authors believe the major reason of heterogeneity and a few inconsistent results are primarily linked with the different instrument used to assess the same outcome, as mentioned in the summary table. Apparently, the interventions are similar, but, on a zoomed scale, we find the difference in contents of training, modes of delivery, and duration and frequency of sessions are quite different. Furthermore, the follow-ups were by telephone,⁵⁷ while others use mail^{48,58} or face to face sessions. All these could be taken as a potential source of variability. Besides this, many studies proffer some flaws; for instance, two studies have too few patients in their sample, which make the results a bit dubious and less generalizable.^{44,57} The longest study in the US evaluating the impact of CPs interventions, though, mentioned significant beneficial effects for the patients and

healthcare system; however, this can be criticized for the free medications which were given to patients as an incentive to attract.⁴⁵ This potential factor can lead to an interpretation that free access to medicine may itself be self-sufficient to have a good impact on patient clinical outcomes, irrespective of the specific intervention. Another considerable drawback in the same study was the CPs interventions cover 75% of patients, and still 25% of patients were given the intervention in the hospital, while there was no clear-cut data depicting this separation and, thus, contaminating the study. Furthermore, a pediatric population was also added to the study, but no data accounts for this population.⁴⁵ Finally, the use of different scales in various studies offers a significant limitation, which may lead to non-reproducible results. Hence, there is a need to standardize the methodology, research designs, tools, as well as the intervention. This will further minimize the biases and strengthen the base. Although 11/14 outcomes have shown promising results, we still need further data in the form of large RCTs with standardized tools of research to expand our understanding on this issue.

Despite some inherent limitations in studies included in this review; nevertheless, results were coherent and sufficiently comprehensive for the positive impact of the CP-GP collaboration in inhalation technique correction, medication use, asthma control, knowledge, and adherence. Other outcomes also appear promising, but need well designed clinical trials.

Conclusion

The community pharmacy setting has emerged as a beneficial point of contact for management of asthma. The overall evidence base is consistent in favor of CP-GP collaborative practice in asthma management and supports implementation of this collaborative practice between CP-GP. The results of this research advocate the active engagement of CPs in asthma management and rational drug use. The evidence is sufficiently comprehensive to favor CPs intervention for inhalation technique correction, asthma knowledge and control, drug adherence, QoL, and rationalizing drug use. The time has reached CPs to individualize patient care plans and practice evidence based pharmaceutical care. The Australian concept of “asthma friendly pharmacies” could serve as one of the millennium goals to make the retail pharmacy setup into a modern future “health hub”.

Disclosure

The abstract of this paper was presented at the Annual Congress on Medicine, as a poster presentation/conference

talk with interim findings. The poster’s abstract was published in Biology and Medicine, ISSN: 0974-8369. <https://www.omicsonline.org/proceedings/a-systematic-review-and-meta-analysis-of-the-impact-of-collaborative-practice-between-community-pharmacist-and-general-practitioner-99343.html>. The authors report no conflicts of interest in this work.

References

1. Global Asthma Network. *The Global Asthma Report 2018*. The Global Asthma Network: Vol. 5. Auckland, New Zealand; 2018. ISBN: 978-0-473-29125-9/978-0-473-29126-6 (Electronic).
2. Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention*. The Global Initiative for Asthma: Fontana, WI; 2018.
3. Burney P, Jarvis D, Perez-Padilla R. The global burden of chronic respiratory disease in adults. *Int J Tuberc Lung Dis*. 2015;19(1):10–20. doi:10.5588/ijtld.14.0446
4. WHO. *Global Surveillance, Prevention and Control of Chronic Respiratory Diseases*. World Health Organization: Geneva; 2007. ISBN 978 92 4 156346 8.
5. Garcia-Cardenas V, Sabater-Hernandez D, Kenny P, Martinez-Martinez F, Faus MJ, Benrimoj SI. Effect of a pharmacist intervention on asthma control. A cluster randomised trial. *Respir Med*. 2013;107(9):1346–1355. doi:10.1016/j.rmed.2013.05.014
6. Bradley CL, Luder HR, Beck AF, et al. Pediatric asthma medication therapy management through community pharmacy and primary care collaboration. *J Am Pharm Assoc*. 2016;56(4):455–460. doi:10.1016/j.japh.2016.03.007
7. Barton C, Proudfoot J, Amoroso C, et al. Management of asthma in Australian general practice: care is still not in line with clinical practice guidelines. *Prim Care Respir J*. 2008;18(2):100–105. doi:10.3132/pcrj.2008.00059
8. Wiener-Ogilvie S, Pinnock H, Huby G, Sheikh A, Partridge MR, Gillies J. Do practices comply with key recommendations of the British asthma guideline? If not, why not? *Prim Care Respir J*. 2007;16(6):369–377. doi:10.3132/pcrj.2007.00074
9. Watkins K, Bourdin A, Trevenen M, et al. Opportunities to develop the professional role of community pharmacists in the care of patients with asthma : a cross-sectional study. *NPJ Primary Care Respir Med*. 2016;26. doi:10.1038/nppcr.2016.82
10. Benavides S, Rodriguez JC, Maniscalco-Feichtl M. Pharmacist involvement in improving asthma outcomes in various healthcare settings: 1997 to present. *Ann Pharmacother*. 2009;43(1):85–97. doi:10.1345/aph.1K612
11. Felix J, Ferreira D, Afonso-Silva M, et al. Social and economic value of portuguese community pharmacies in health care. *BMC Health Serv Res*. 2017;17:1. doi:10.1186/s12913-017-2525-4
12. Alotaibi HS, Shivanandappa TB, Nagarethinam S. Contribution of community pharmacists in educating the asthma patients. *Saudi Pharm J*. 2016;24(6):685–688. doi:10.1016/j.jsps.2015.06.002
13. Carter BL. Primary care physician-pharmacist collaborative care model: strategies for implementation. *Pharmacotherapy*. 2016;36(4):363–373. doi:10.1002/phar.1732
14. Hisashige A. The effectiveness and efficiency of disease management programs for patients with chronic diseases. *Glob J Health Sci*. 2013;5(2):27–48. doi:10.5539/gjhs.v5n2p27
15. Gums TH, Carter BL, Milavetz G, et al. Physician-pharmacist collaborative management of asthma in primary care. *Pharmacotherapy*. 2014;34(10):1033–1042. doi:10.1002/phar.1468
16. Berry TM, Prosser TR, Wilson K, Castro M. Asthma friendly pharmacies: A model to improve communication and collaboration among pharmacists, patients, and healthcare providers. *J Urban Heal*. 2011;88(SUPPL. 1):113–125. doi:10.1007/s11524-010-9514-9

17. McBane SE, Dopp AL, Abe A, et al. Collaborative drug therapy management and comprehensive medication management - 2015. *Pharmacotherapy*. 2015;35(4):e39–e50. doi:10.1002/phar.1563
18. Yong YV, Shafie AA. How much does management of an asthma-related event cost in a Malaysian suburban hospital? *Value Heal Reg Issues*. 2018;15:6–11. doi:10.1016/j.vhri.2017.05.001
19. Crespo-Gonzalez C, Fernandez-Llimos F, Rotta I, Correr CJ, Benrimoj SI, Garcia-Cardenas V. Journal of the American pharmacists association characterization of pharmacists' interventions in asthma management: A systematic review. *J Am Pharm Assoc*. 2018;1–10. doi:10.1016/j.japh.2017.12.009
20. Portlock BJ, Holden M, Patel S. Original papers A community pharmacy asthma MUR project in Hampshire and the Isle of Wight. *Pharm J*. 2009;282(January):109–112.
21. Bollmeier SG, Prosser TR. Community pharmacy-based asthma services: current perspectives and future directions. *Integr Pharm Res Pract*. 2014;3:49–70. doi:10.2147/IPRP.S47331
22. Garcia-Cardenas V, Armour C, Benrimoj SI, Martinez-Martinez F, Rotta I, Fernandez-Llimos F. Pharmacists' interventions on clinical asthma outcomes: A systematic review. *Eur Respir J*. 2016;47(4):1134–1143. doi:10.1183/13993003.01497-2015
23. Adunlin G, Mahdavian S. The effectiveness of pharmacist interventions on asthma management: a systematic review. *J Asthma Allergy Educ*. 2012;3(6):264–273. doi:10.1177/2150129712464775
24. Mes MA, Katzer CB, Chan AHY, Wileman V, Taylor SJC, Horne R. Pharmacists and medication adherence in asthma: a systematic review and meta-analysis. *Eur Respir J*. 2018;52(2):1800485. doi:10.1183/13993003.00485-2018
25. Brown D, Portlock J, Rutter P. Review of services provided by pharmacies that promote healthy living. *Int J Clin Pharm*. 2012;34(3):399–409. doi:10.1007/s11096-012-9634-2
26. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med*. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100
27. Effective Practice and Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews; 2016. Available from: <http://epoc.cochrane.org/resources/epoc-resources-review-authors>. Accessed November 25, 2018.
28. Khan KS, Kunz R, Kleijnen J, Antes G. *Systematic Reviews to Support Evidence-Based Medicine*. 2nd ed. London: Hodder & Stoughton Ltd; 2011.
29. Verhaagen AP, Ferreira ML. Forest plots. *J Physiother*. 2014;60(3):170–173. doi:10.1016/j.jphys.2014.06.021
30. Fletcher J. What is heterogeneity and is it important? *Br Med J*. 2007;334(7584):91–94. doi:10.1136/bmj.39038.614317.AE
31. Ried K. Interpreting and understanding meta-analysis graphs. A practical guide. *Aust Fam Physician*. 2006;35(8):1–24.
32. Israel H, Richter RR. A guide to understanding meta-analysis. *J Orthop Sport Phys Ther*. 2011;41(7):496–504. doi:10.2519/jospt.2011.3333
33. Stephenson J. Explaining the forest plot in meta-analyses. *J Wound Care*. 2017;26(11):2017–2018. doi:10.12968/jowc.2017.26.11.611
34. Sedgwick P. How to read a forest plot in a meta-analysis. *BMJ*. 2012;351(December):h4028. doi:10.1136/bmj.h4028
35. Sedgwick P. Meta-analyses: heterogeneity and subgroup analysis. *BMJ*. 2013;346(7914):9–11. doi:10.1136/bmj.f4040
36. Zlowodzki M, Poolman RW, Kerkhoffs GM, Tornetta P, Bhandari M. How to interpret a meta-analysis and judge its value as a guide for clinical practice. *Acta Orthop*. 2007;78(5):598–609. doi:10.1080/17453670710014284
37. Hak T, van Rhee H, Suurmond R. How to interpret results of meta-analysis. (Version 1.3). 1st ed. Rotterdam, The Netherlands: Erasmus Rotterdam Institute of Management; 2016:1–21. doi:10.2139/ssrn.3241367
38. Chong-Ho Yu PD. *Meta-Analysis and Effect Size*. 2010:1–24. Available from: <http://www.creative-wisdom.com/teaching/WBI/es.shtml>. Creative Wisdom.
39. Faraone SV. Interpreting estimates of treatment effects: implications for managed care. *P T J Formul Manag*. 2008;33(12):700–711. doi:10.1093/jicru/ndm032
40. Durlak JA. How to select, calculate, and interpret effect sizes. *J Pediatr Psychol*. 2009;34(9):917–928. doi:10.1093/jpepsy/jsp004
41. Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. *J Exp Psychol Gen*. 2012;141(1):2–18. doi:10.1037/a0024338
42. Charrois T, Newman S, Sin D, Senthilselvan A, Tsuyuki RT. Improving asthma symptom control in rural communities: the design of the better respiratory education and asthma treatment in hinton and edson study. *Can Pharm J*. 2006;139(4):44–50. doi:10.1016/j.cct.2004.07.004
43. Manfrin A, Tinelli M, Thomas T, Krska J. A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients. *BMC Health Serv Res*. 2017;17(1):300. doi:10.1186/s12913-017-2245-9
44. Crowder T. *An Evaluation of Community Pharmacists Applying the Patient Centered Care Approach to Ambulatory Oregon Health Plan Asthmatics in a Managed Care Setting*. 2000. Oregon States University.
45. Bunting BA, Cranor CW. The asheville project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. *J Am Pharm Assoc*. 2006;46(2):133–147. doi:10.1331/154434506776180658
46. Saini B, Krass I, Armour C. Development, implementation, and evaluation of a community pharmacy-based asthma care model. *Ann Pharmacother*. 2004;38(11):1954–1960. doi:10.1345/aph.1E045
47. Armour C, Reddel HK, LeMay KS, et al. Feasibility and effectiveness of an evidence-based asthma service in Australian community pharmacies: a pragmatic cluster randomized trial. *J Asthma*. 2013;50(3):302–309. doi:10.3109/02770903.2012.754463
48. Bereznicki B, Peterson G, Jackson S, Haydn Walters E, Deboos I, Hintz P. Perceived feasibility of a community pharmacy-based asthma intervention: A qualitative follow-up study. *J Clin Pharm Ther*. 2011;36(3):348–355. doi:10.1111/j.1365-2710.2010.01187.x
49. Armour C, Bosnic-Anticevich S, Brilliant M, et al. Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. *Thorax*. 2007;62(6):496–502. doi:10.1136/thx.2006.064709
50. Cordina M, McElroy JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. *Pharmacotherapy*. 2001;21(10):1196–1203. doi:10.1592/phco.21.15.1196.33894
51. Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of pharmacist intervention for asthma control improvement. *Eur Respir J*. 2008;31(4):790–799. doi:10.1183/09031936.00112007
52. Mangiapane S, Schulz M, Mühlh S, Ihle P, Schubert I, Waldmann HC. Community pharmacy-based pharmaceutical care for asthma patients. *Ann Pharmacother*. 2005;39(11):1817–1822. doi:10.1345/aph.1G180
53. McLean W, Gillis J, Waller R. The BC community pharmacy asthma study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. *Can Respir J*. 2003;10(4):195–202. doi:10.1155/2003/736042
54. Amirthalingam ARS. An evaluation of a community pharmacy based, pharmacist-led intervention package targeted to the patients' adherence status, to achieve and maintain target blood pressure (BP) control by optimising antihypertensive medicine adherence; 2017. Available from: <http://etheses.bham.ac.uk/7834/>. Accessed November 25, 2018.
55. Bereznicki BJ, Peterson GM, Jackson SL, Walters H, Fitzmaurice K, Gee P. Pharmacist-initiated general practitioner referral of patients with suboptimal asthma management. *Pharm World Sci*. 2008;30(6):869–875. doi:10.1007/s11096-008-9242-3

56. Schulz M, Verheyen F, Muhlig S, et al. Pharmaceutical care services for asthma patients: a controlled intervention study. *J Clin Pharmacol*. 2001;41(6):668–676. doi:10.1177/00912700122010438
57. Barbanel D, Eldridge S, Griffiths C. Can a self-management programme delivered by a community pharmacist improve asthma control? A randomised trial. *Thorax*. 2003;58(10):851–854. doi:10.1136/thorax.58.10.851
58. Bereznicki BJ, Peterson G, Jackson S, et al. Uptake and effectiveness of a community pharmacy intervention programme to improve asthma management. *J Clin Pharm Ther*. 2013;38(3):212–218. doi:10.1111/jcpt.12017
59. Narhi U, Airaksinen M, Tanskanen P, Erlund H. Therapeutic outcomes monitoring by community pharmacists for improving clinical outcomes in asthma. *J Clin Pharm Ther*. 2000;25(3):177–183. doi:10.1046/j.1365-2710.2000.00276.x
60. Saini B, LeMay K, Emmerton L, et al. Asthma disease management- Australian pharmacists' interventions improve patients' asthma knowledge and this is sustained. *Patient Educ Couns*. 2011;83(3):295–302. doi:10.1016/j.pec.2011.05.001
61. Grainger-Rousseau TJ, McInlay JC. Grainger-Rousseau,1997.pdf. *J Appl Ther*. 1997;1(1):145–161.
62. Herborg H, Soendergaard B, Froekjaer B, et al. Improving drug therapy for patients with asthma-part 1: patient outcomes. *J Am Pharm Assoc*. 2001;41(4):539–550. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11486980>
63. Bereznicki BJ, Peterson GM, Jackson SL, Walters EH, Fitzmaurice KD, Gee PR. Data-mining of medication records to improve asthma management. *Med J Aust*. 2008;189(1):21–25.
64. Bereznicki B, Peterson G, Jackson S, Walters EH, Gee P. The sustainability of a community pharmacy intervention to improve the quality use of asthma medication. *J Clin Pharm Ther*. 2011;36(2):144–151. doi:10.1111/j.1365-2710.2010.01165.x

Journal of Asthma and Allergy

Dovepress

Publish your work in this journal

The Journal of Asthma and Allergy is an international, peer-reviewed open-access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and

new therapies. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-asthma-and-allergy-journal>